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Abstract 
Streptococcus pneumoniae, a common bacterium of the human nasopharynx, can cause severe 
local infections such as otitis media and also life-threatening invasive diseases including 
pneumonia, sepsis and meningitis. Moreover, S. pneumoniae is the most common cause of 
community-acquired bacterial pneumonia. The respiratory mucosa of healthy individuals is 
scattered with sentinel cells including dendritic cells (DCs), which have an extraordinary 
capacity to interact with T and B cells and modulate their responses to invading pathogens. 
Because in the lung DCs are situated in close vicinity to alveolar epithelial cells, it appears 
conceivable that interactions between DCs and S. pneumoniae can strongly influence the 
outcome of the infection process. To clarify the specific contribution of pulmonary DCs to 
host defense against S. pneumoniae, bone marrow chimera mice were generated from CD11c-
DTR transgenic mice since DCs of these mice can be transient depleted by administration of 
consecutive doses of diphtheria toxin (DT). Strikingly, depletion of DCs rendered those mice 
much more resistant to respiratory infection with S. pneumoniae than non-depleted animals. 
Thus, DC-depleted mice exhibited delayed bacterial systemic dissemination, significantly 
reduced bacterial loads in the infected organs and lower levels of serum inflammatory 
mediators than non-depleted animals. The superior resistance of DC-depleted mice to 
S. pneumoniae was associated with a better capacity to restrict pneumococci extrapulmonary 
dissemination. Furthermore, it was demonstrated that S. pneumoniae disseminated from the 
lungs into the regional lymph nodes in a cell-independent manner and that this direct way of 
dissemination was much more efficient in the presence of DCs. The possibility that 
S. pneumoniae might exploit the capacity of DCs to break tissue barriers to facilitate its 
extrapulmonary dissemination was then investigated. The obtained results provided evidence 
that S. pneumoniae induced the expression and activation of matrix metalloproteinase-9 
(MMP-9) in cultured bone marrow-derived DCs. MMP-9 is a protease involved in the 
breakdown of extracellular matrix proteins and is critical for DC trafficking across 
extracellular matrix and basement membranes during the migration from the periphery to the 
lymph nodes. Furthermore, depletion of DCs correlated with significant decreased MMP-9 
expression in the lungs of S. pneumoniae-infected mice.  
In summary, the results of this thesis provide direct in vivo evidence that S. pneumoniae 
exploits DCs to disseminate from the initial site of infection. Therefore, modulation of DCs 
during pneumococcal pneumonia might provide an interesting means to prevent or delay 
extrapulmonary bacterial dissemination. 
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1. Introduction 
1.1. Streptococcus pneumoniae 
1.1.1. Overview 
Streptococcus pneumoniae (pneumococcus) is a gram-positive encapsulated bacterium that 
grows in pairs or chains and is facultatively anaerobic [1]. It was first isolated in 1881 
simultaneously and independently by George M. Sternberg and Louis Pasteur [2]. 
Pneumococci are alpha hemolytic microorganisms which are often found as a normal 
commensal in the nasopharynx of healthy adults and children [3]. However, S. pneumoniae 
can also cause diseases that range in severity from life-threatening meningitis, septicemia, and 
pneumonia to more mild infections such as sinusitis and acute otitis media [4]. Although all 
age groups may be affected by S. pneumoniae, the highest rate of pneumococcal disease 
occurs in young children and in the elderly population [5]. In addition, persons affected by 
chronic conditions and immune deficiencies are at increased risk. S. pneumoniae is a major 
cause of morbidity and mortality. Thus, it has been estimated that more than 10 million 
children under 5 years of age are affected by pneumococcal disease every year [6]. 
S. pneumoniae is surrounded by a polysaccharide capsule that constitutes the basis for the 
serotyping classification of the bacterium in more than 90 serotypes [7]. The distribution of 
the different serotypes varies between geographic regions. While serotypes 6, 14, 19, and 23 
are the most common serogroups worldwide, serotypes 1, 5, and 8 are the major cause of 
invasive pneumococcal disease in young children in developing countries [8]. Approximately 
90% of the most frequent isolates belonging to 23 serotypes have been included in the 23-
valent pneumococcal vaccine [9]. Following implementation of the pneumococcal conjugate 
vaccine, the incidence of invasive pneumococcal diseases has significantly declined in both 
children and adults [10, 11]. However, the emergence of serotypes not encompassed in the 
vaccine combination is a matter of concern [12]. In addition, antibiotic resistance among 
pneumococci has dramatically increased during the last three decades [13]. Therefore, 
diseases caused by S. pneumoniae remain a significant public health problem all over the 
world and renewed efforts are now being made to better understand the pathogenesis of 
pneumococcal diseases. 
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1.1.2. Virulence factors 
As an extracellular bacterial pathogen, S. pneumoniae needs to attach to host cells, to replicate 
and to escape clearance by the host immune system. All these pathogenic functions are 
enabled by the coordinated expression of a wide array of virulence factors (Fig. 1). Thus, 
attachment of S. pneumoniae to eukaryotic cells is meditated by a diverse group of bacterial 
surface molecules including cell wall components, choline binding proteins, LPxTG proteins, 
lipoproteins, and non-classical adhesins such as surface associated enzymes [14]. 
Furthermore, S. pneumoniae has developed a number of strategies to avoid phagocytosis by 
the host cells. Among them, the capsule protects against phagocytic clearance by blocking the 
deposition and function of opsonins directed against cell surface antigens [15]. In addition, 
the pneumococcal capsule can reduce bacterial trapping by neutrophil extracellular traps 
(NETs) [16], killing by defensins [17], and clearance by mucus [18]. Other virulence factors 
such as the pneumococcal surface protein A (PspA), and the toxin pneumolysin are mainly 
involved in the induction of inflammation. The most relevant virulence factors expressed by 
S. pneumoniae are described below.  
 
 
 
Figure 1: Schematic representation of the virulence factors expressed by S. pneumoniae. 
Adopted without modifications from Briles et al., 1998 [19]. 
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1. Capsule 
The capsule has long been considered to be the primary virulence factor of S. pneumoniae 
where its pathogenesis is underscored by the high level of attenuation exhibited by 
encapsulated strains [20, 21]. The pneumococcus capsule consists of chains of 
monosaccharides covalently attached to the outer surface of the cell wall peptidoglycan [22]. 
The chemical structure as well as the thickness of the capsule determines the ability of the 
different serotypes to survive in the bloodstream and possibly cause invasive disease [23]. 
More than 90 distinct capsular serotypes have been identified according to reactivity with 
polyclonal or monoclonal antibodies [7]. They differ in terms of activation of the alternative 
pathway of complement [24-26], deposition and degradation of complement components on 
the capsule [27, 28], resistance to phagocytosis [26, 29, 30], and the ability to induce antibody 
production [31]. Given its essential role in the pathogenesis of S. pneumoniae infection, 
capsular polysaccharides have been used in the 23-valent pneumococcal polysaccharide 
vaccine PNEUMOVAX 23® and the pediatric multivalent pneumococcal conjugated vaccines. 
 
2. Cell wall 
The cell wall of S. pneumoniae is composed of teichoic acids (TA) linked via a 
phosphodiester bond to the peptidoglycan backbone and lipoteichoic acids (LTA) linked to 
the cell membrane via a C-terminal fatty acyl group [32]. TA and LTA are potent pro-
inflammatory constituents of S. pneumoniae. They are composed of repetitive oligosaccharide 
units conjugated to phosphorylcholine [33]. The inflammatory reaction associated with 
typical pneumococcal diseases such as otitis media, meningitis, and pneumonia can be 
mimicked in animals after injection of purified cell wall or its degradation products [34-36]. 
Furthermore, it has been shown that the pneumococcal cell wall activates the alternative 
pathway in vitro [37, 38] and that the activation of the complement system may be involved 
in the induction of lung and central nervous system inflammation by S. pneumoniae in vivo 
[36, 39]. Other central mediators of the inflammatory process induced by the pneumococcal 
cell wall are interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α). Purified cell wall 
and TA are powerful inducers (even stronger than endotoxin) of IL-1 production by human 
peripheral monocytes [40] whereas LTA is able to trigger TNF-α release [41]. Furthermore, 
the muramyl dipeptide, a structural component of the pneumococcal peptidoglycan, can also 
induce production of cytokine IL-1 [42]. 
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3. Pneumolysin 
Pneumolysin is a cytoplasmatic enzyme that belongs to the family of the thiol-activated toxins 
[43]. It is produced as a 52 kDa soluble protein that is released upon bacterial lysis induced by 
autolysin. At high concentrations, it oligomerizes in the membrane of target cells to form a 
large ring-shaped transmembrane pore. The pore is 260 Å in diameter and is composed of 
approximately 40 monomeric subunits [44]. At lower concentrations, the toxin has several 
effects on different cell types, including stimulation of inflammatory cytokines by human 
monocytes [45], inhibition of the cilia beating on human respiratory epithelial cells, disruption 
of the monolayers in cultured respiratory epithelium [46, 47], induction of apoptosis of 
murine dendritic cells [48] and neuronal cells [49-51], reduction of the bactericidal activity as 
well as migration of neutrophils [52], and inhibition of lymphocyte proliferation and antibody 
synthesis [53]. Furthermore, pneumolysin has been reported to activate the classical 
complement pathway [54]. Recognition of pneumolysin by immune cells is mediated by Toll-
like receptor 4 [55]. The importance of pneumolysin for S. pneumoniae infection is 
highlighted by the lower level of virulence exhibited by pneumolysin-negative mutants in 
comparison with their parental strains [56] and, by the extended survival of pneumolysin-
immunized mice after challenge with pneumococci of different serotypes [57-59]. 
Pneumolysin is found in virtually all pneumococcal isolates and its amino acid sequence is 
well conserved, although a small number of variants have been described [60, 61]. 
 
4. Pneumococcal surface protein A 
Pneumococcal surface protein A (PspA) is a surface-exposed protein, which varies in 
structure and antigenicity between the different pneumococcal strains. PspA is expressed by 
most clinical isolates [62] and it has a unique structure with similarities to other surface 
proteins in gram-positive bacteria (e.g. M proteins of group A streptococci) [63]. PspA has 
been reported to inhibit C3-mediated opsonization of S. pneumoniae [64] and disruption of 
the pspA gene resulted in reduction or even loss of bacterial virulence [65, 66]. Furthermore, 
passive immunization of mice with polyclonal or monoclonal antibodies raised against PspA 
or active immunization with either recombinant PspA or its N-terminal fragment has been 
shown to be protective against challenge with pneumococci of various capsular serotypes [67-
69]. 
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5. Autolysin (LytA) 
The autolysin LytA is an N-acetylmuramic acid-L-alanine amidase that is located in the cell 
envelope of the pneumococcus. This enzyme is involved in the process of cell division by 
cleaving the peptidoglycan in the cell wall. The name autolysin is due to the fact that it 
induces lysis of pneumococci under certain conditions such as nutrient starvation during the 
stationary phase of growth [70]. 
Immunization of mice with autolysin confers some level of protection against challenge with 
a virulent wild-type strain [71]. In addition, LytA-deficient S. pneumoniae mutant strains 
were shown to have reduced virulence in murine models of pneumonia and bacteremia [71-
74]. The functional activity of autolysin seems to be mediated by the release of cytoplasmic 
bacterial proteins including pneumolysin as well as cell wall constituents [75]. 
 
6. Adhesins 
For successful colonization and establishment of infection S. pneumoniae must first attach to 
the epithelial surface. This process is mediated by the expression of adhesins that target host 
components including lipoproteins, choline-binding proteins (CBPs), proteins with an LPxTG 
motif and non-classic surface proteins. In particular, CBPs and non-classic surface proteins 
that lack a leader peptide or membrane-anchor motif display adhesive functions [14, 76]. 
Proteins with an LPxTG motif have rather enzymatic activities which unveil host cell 
receptors and aid the bacterial adherence to the host cells [76]. Unlike LPxTG proteins, CBPs 
are non-covalently linked to the phosphorylcholine of the pneumococcal cell wall. 
Interestingly, phosphorylcholine itself has been shown to function as an adhesin by 
recognizing the platelet-activating factor receptor (PAFR) of host cells [77, 78]. Among 
CBPs, the major pneumococcal adhesin in the nasopharyngeal cavity is the multifunctional 
pneumococcal surface protein C (PspC). PspC interacts with the ectodomain of the polymeric 
immunoglobulin receptor in a human-specific manner [79-81] and with the innate immune 
components factor H and C3 which promotes pneumococcal adherence as well as immune 
evasion [82-84]. 
In addition, SlrA (streptococcal lipoprotein rotamase A) and PpmA (putative proteinase 
maturation protein A) have been shown to be involved in pneumococcal colonization since 
deficiency in either of these lipoproteins reduced bacterial adherence to and internalization by 
epithelial and endothelial cells and resulted in rapid bacterial clearance from the nasopharynx 
in a murine pneumonia model [85, 86]. The pneumococcal surface adhesin A (PsaA) is part of 
an ABC transporter complex for manganese and thought to interact with E-cadherin [87]. 
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Mutants lacking PsaA exhibited reduced adherence capacity to human epithelial cells in vitro 
[88] as well as a reduced ability to colonize the nasopharynx in vivo [89]. 
In order to gain access to the submucosa and the bloodstream, pneumococci have been 
reported to breach barriers including the epithelium and endothelium as well as the 
extracellular matrix (ECM) by interacting with plasminogen and fibronectin [90, 91]. 
Fibronectin-binding was reported for PavA (pneumococcal adherence and virulence factor A), 
whereas PavB and PfbA (plasmin- and fibronectin-binding protein A) are able to bind both 
fibronectin and plasminogen [92]. In addition, the glycolytic enzymes α-enolase, GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase) and the choline-binding protein E (CBPE) have 
also been shown to bind human plasminogen [91, 93, 94]. After recruitment of host 
plasminogen to the bacterial surface the zymogen is converted to the serine protease plasmin 
which promotes degradation of various ECM compounds such as fibrin and laminin [76]. In 
addition, pneumococci have been shown to produce proteases such as the zinc 
metalloproteinase C (ZmpC) that activates human matrix metalloproteinase 9 (MMP-9) [95]. 
Thus, ZmpC can contribute to tissue invasion, since MMP-9 cleaves gelatin and collagen of 
the ECM [96]. 
 
1.1.3. Antibiotic resistance of S. pneumoniae 
The prevalence of antibiotic-resistant S. pneumoniae has increased worldwide. Since the first 
pneumococcal isolate resistant to penicillin was isolated from a patient in Australia in 1967 
[97], penicillin-resistant pneumococci have spread all over the world [98, 99]. In some parts 
of Latin America the rates of penicillin resistance among the pneumococci are as high as 60% 
and in some countries in Asia as high as 80% [100, 101]. Resistance to penicillin may occur 
in combination with resistance to other antimicrobial agents [102]. Pneumococci resistant to 
more than two separate classes of antibiotics are considered to be multi-resistant. Thus, strains 
of S. pneumoniae exhibiting multiple antibiotic resistance including penicillin, tetracycline, 
erythromycin, clindamycin, trimethoprim-sulfamethoxazole, and chloramphenicol were 
initially reported in 1977 in South Africa [103] and subsequently in Europe [4, 104, 105] as 
well as in the United States [106]. Penicillin-resistant and multiple resistant strains belonged 
predominantly to serotypes 6, 19, 14, and 23 [107-109], with 23F being the most associated 
with multi-resistance [110, 111]. Pneumococcal resistance to essential antimicrobials is a 
serious and rapidly increasing problem worldwide. 
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1.1.4. Infections caused by S. pneumoniae 
S. pneumoniae is a frequent colonizer of the human nasopharynx. From this location, the 
bacterium can spread to the upper and lower respiratory tract and can cause non-invasive 
diseases such as otitis media or non-bacteremic pneumonia, which is an infection of the lower 
respiratory tract without detectable spread of bacteria to the bloodstream. However, 
S. pneumoniae can also cause severe invasive diseases including bacteremia (bacterial 
infection of the blood), meningitis and bacteremic pneumonia, which is an inflammation of 
the lungs, with pneumococci also reaching the bloodstream [4]. Pneumococci are transmitted 
from person to person via respiratory droplets. Infection usually begins with the upper 
respiratory tract and then travels into the lungs. Pneumonia occurs when the bacteria find their 
way deep into the lungs, to the alveoli. Once in the alveoli, S. pneumoniae begins to grow and 
multiply resulting in the extravasation of inflammatory cells and fluids at the site of infection 
into the alveoli. This inflammation of the lungs is known as pneumonia. 
The incidence of pneumococcal pneumonia is highest in children under 2 years of age, in 
people over 60 years of age and people with immunodeficiency [105, 106]. Rudan et al. 
reported that most episodes (> 95%) of early childhood pneumonia in children aged 0 - 4 
years occur in developing countries, at an incidence rate of 0.28 episodes per year [112]. The 
incidence of hospitalized pneumonia in adults has been estimated at around 2.75 - 2.96 per 
1000 population, with a steeply cumulative incidence with increasing age, and in-hospital 
mortality of around 14% [113]. 
S. pneumoniae can also spread from the upper respiratory tract to the middle ear, where it 
causes inflammation followed by accumulation of middle ear secretions. Inflammation or 
infection of the middle ear has been termed acute otitis media (AOM). AOM is one of the 
most frequent bacterial infections in children aged < 5 years. S. pneumoniae causes 30% -
 50% of all cases of AOM worldwide [114]. 
From the upper respiratory tract, the lungs or the middle ear pneumococci can invade the 
bloodstream and move across the meninges causing meningitis [115]. The meninges are the 
membranes that surround and protect the brain and spinal cord. They are filled with liquid 
where S. pneumoniae can freely multiply. The risk of developing pneumococcal meningitis is 
highest among young children, older adults, persons with chronic illnesses, and 
immunocompromised individuals [116, 117]. Even with advances in medical care, the case-
fatality rate has a range of 16% - 37% in adults and 1% - 3% in children [118]. Those who 
survive the disease have a 30% - 52% risk of neurological sequelae [119, 120]. 
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1.1.5. Pneumococcal vaccines 
The first attempt to vaccinate against S. pneumoniae was performed using whole killed 
pneumococci. However, this approach failed due to the adverse side effects caused by the 
high amounts of inocula required for inducing an immune response. The breakthrough in 
pneumococcal vaccine took place in the 1930s, after the development of pneumococcal 
serotyping and the demonstration of the immunogenicity of purified capsular polysaccharides. 
Today, more than 90 different serotypes based on differences in their polysaccharide capsule 
have been described [7]. The prevalence of the different serotypes is unequal, with the 
majority of pneumococcal diseases caused by around 20 serotypes. The predominant serotype 
varies with age, geography and site of infection [121]. Currently two types of vaccines, the 
pneumococcal polysaccharide vaccine (PPV) and the pneumococcal polysaccharide 
conjugated vaccine (PVC), have been approved for the prevention of pneumococcal disease. 
The current available pneumococcal polysaccharide vaccine is Pneumovax®23 (Merck), 
which is comprised of purified polysaccharides of 23 different serotypes. This 23-valent 
vaccine contains 23 capsular polysaccharide antigen serotypes that are responsible for about 
90% of invasive pneumococcal infections [122-124]. However, children under two years of 
age and immunodeficient individuals respond poorly to this vaccine, thus reducing the 
protective value of the vaccine in two major target populations [125, 126]. In addition, the 
vaccine has no significant effect on nasopharyngeal carriage. To overcome these limitations, a 
new generation of protein-polysaccharide pneumococcal vaccines based on the conjugation of 
selected capsular polysaccharide to a protein carrier has been generated. The protein carriers 
induce a T cell-dependent immune response to the polysaccharides, leading to immunological 
memory and boosting upon repeated injection. A 7-valent conjugated vaccine that targets the 
most common serotypes of pneumococci causing diseases in children is currently available 
[127]. Because the number of other pneumococcal serotypes is becoming increasingly more 
common in children, a pneumococcal conjugated vaccine containing six additional 
polysaccharides has been generated (13-valent) [128]. Searching for new pneumococcal 
vaccines is still an ongoing issue because although the rates of invasive pneumococcal 
infections caused by the capsular serotypes included in the conjugated vaccine have declined, 
rates of invasive diseases caused by non-vaccine serotypes have increased in many places 
[12]. This phenomenon is known as “serotype replacement”. 
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1.2. The host innate immune response to S. pneumoniae 
1.2.1. Immune recognition of S. pneumoniae 
The innate host defense mechanisms against S. pneumoniae include opsonization, activation 
of complement and coagulation cascades, phagocytosis and activation of pro-inflammatory 
signaling pathways [129]. The recognition of invading pneumococci by the host innate 
immune system is mediated by pathogen recognition receptors (PRRs). The most important 
PRRs for S. pneumoniae are the members of the toll-like receptor (TLR) family, particularly 
the TLR2, TLR4, and TLR9 [55, 130, 131]. TLR2 has been reported to recognize lipoteichoic 
acid and cell wall peptidoglycan [130, 132, 133]. In a meningitis model, mice deficient in 
TLR2 expression displayed increased disease severity and decreased survival times compared 
with wild-type counterparts [134]. On the other hand, during pneumococcal pneumonia 
TLR2-deficient mice showed no differences in bacterial clearance and morbidity compared to 
the wild-type animals, although they exhibited reduced pulmonary inflammation [135]. 
Furthermore, van Rossum et al. [136] demonstrated in a nasopharyngeal colonization model 
reduced clearance of pneumococci after intranasal challenge, providing evidence that TLR2 
also plays a role during carriage of S. pneumoniae. A protective role in pneumococcal 
pneumonia also has been demonstrated for TLR4 [137], although the protective effect is 
restricted to airway surfaces since the absence of TLR4 had no effect on survival rates and 
blood bacterial counts after intravenous infection of mice [138]. The bacterial ligand for 
TLR4 seems to be pneumolysin [55, 139]. Pneumolysin as well as DNA are released by 
S. pneumoniae that undergo apoptosis. Unmethylated cytosine-phosphate-guanosine (CpG) 
motifs in bacterial DNA are recognized by TLR9 [140]. Although TLR9 has been shown to 
be redundant in the control of nasopharyngeal colonization and pneumococcal meningitis 
[131, 141], TLR9-deficient mice exhibited reduced survival rates and enhanced bacterial 
loads in the lungs during pneumococcal pneumonia [131]. Upon activation, most PRRs 
induce the production of inflammatory mediators, including the cytokines TNF-α, IL-1ß, IL-6 
and IFN-γ (interferon-gamma). 
Other receptors expressed by macrophages critical for host defense against S. pneumoniae 
include the C-type lectin receptor SIGN-R1 (specific intracellular adhesion molecule-3 
grabbing nonintegrin homolog-related 1) and the scavenger receptor MARCO (macrophage 
receptor with collagenous structure). Mice lacking either SIGN-R1 or MARCO exhibited 
increased susceptibility to pneumococcal pneumonia [142, 143]. 
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1.2.2. The role of macrophages and neutrophils 
The control of S. pneumoniae by the host immune system is critically dependent on the 
antimicrobial activities of phagocytic cells, mainly macrophages and neutrophils. The resident 
phagocytes in the lungs are the alveolar macrophages. They are in close proximity to the 
alveoli and responsible for the removal of incoming pathogens [143]. Phagocytosis of 
pathogens by alveolar macrophages is mediated by a variety of receptors including Fc and 
complement receptors (which recognize C3b stabilized on the bacterial surface). Following 
binding to the surface, macrophages phagocytize both opsonized and un-opsonized pathogens, 
which are internalized and killed in a sequence of discrete stages [144]. Depletion of alveolar 
macrophages in mice during pneumococcal pneumonia resulted in an increased lethality, 
indicating a major role of these phagocytic cells in host immune response to S. pneumoniae 
[145]. However, the bacterial clearance was not affected by macrophage depletion. 
Furthermore, the fact that opsonization of S. pneumoniae is critical for phagocytosis by 
macrophages [146, 147] and that murine alveolar macrophages express only low levels of the 
receptors for complement C3b/iC3b (CR1/CR3/CR4) [148] indicates that the protective effect 
of macrophages during pneumococcal pneumonia may not be mediated by the capacity of 
these cells to phagocytize and kill the bacterium but most probably by the production of 
inflammatory cytokines. Thus, alveolar macrophages can release TNF-α and IL-1 to stimulate 
the production of neutrophil chemoattractants such as CXC chemokines including IL-8, KC 
(keratinocyte chemoattractant) and MIP-2 (macrophage inflammatory protein 2) by epithelial 
cells [149-151]. The recruitment of neutrophils from the circulating blood into infected 
airspaces is crucial for the clearance of invading pneumococci since depletion of neutrophils 
rendered mice more susceptible to S. pneumoniae infection [152]. One major function of 
neutrophils consists of phagocytosis after recognition of serum opsonins such as complement 
and immunoglobulins that are attached to invading pathogens. Phagocytized bacteria are 
killed rapidly by proteolytic enzymes, antimicrobial proteins, and reactive oxygen species 
[153]. Another potent mechanism to eliminate pathogens is the formation of neutrophil 
extracellular traps (NETs). NETs are comprised of neutrophil chromatin associated with 
granule proteins that disarm and kill bacteria in an extracellular manner [154]. However, 
pneumococci can escape extracellular killing by degrading the DNA backbone of NETs via 
the surface endonuclease EndA [155]. Although neutrophils are potent effectors of bacterial 
clearance, their recruitment contributes to inflammatory tissue damage [156]. In this regard, 
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alveolar macrophages have been implicated to clear apoptotic neutrophils thereby preventing 
the release of potentially toxic or immunogenic intracellular contents [145]. 
 
1.2.3. The role of dendritic cells 
An additional immune cell population residing in the lungs are the dendritic cells (DCs) 
[157]. DCs were first described by Ralph Steinman and Zanvil Cohn in 1973 [158]. These 
cells are antigen-presenting cells (APCs), which have the unique ability to induce antigen-
specific primary immune responses [159-162]. Newly generated DC progenitors from the 
bone marrow circulate in the bloodstream and home to non-lymphoid tissues, where they 
reside as sentinels for invading pathogens in an immature stage with high phagocytic capacity 
(Fig. 2). 
 
 
Figure 2: The life cycle of dendritic cells (DC). Circulating precursor DCs and immature DCs, 
situated in the tissue, can encounter antigens in the periphery. This leads to the secretion of 
cytokines such as interferon-alpha (IFN-α), which in turn can activate eosinophils, 
macrophages, and natural killer (NK) cells. After antigen capture, the DCs start a maturation 
program and migrate to lymphoid organs where they activate antigen-specific lymphocytes. 
After expansion and differentiation the activated T lymphocytes migrate to the infected tissue. 
T cells as well as DCs activate B cells to become plasma cells, which produce antibodies (Ab) 
that neutralize the pathogen. Adapted with modifications from Palucka and Banchereau, 2002 
[163]. 
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DCs can traverse the tight junctions of epithelial surfaces, interact directly with bacteria on 
the mucosal surface and control local inflammatory responses [164]. In the lungs DCs are in 
close proximity to alveolar epithelial and capillary endothelial cells and form a network of 
sentinel cells specialized to sample inhaled bacterial pathogens [165, 166]. Their encounter 
with antigens by phagocytosis, macropinocytosis, or endocytosis [167, 168] triggers their 
maturation and migration to secondary lymphoid organs, where they perform antigen-
presentation functions. Migration of DCs involves a coordinated action of several 
chemokines. Upon maturation DCs down-regulate chemokine receptors which would drive 
their migration towards inflammatory sites (such as CCR1, CCR2 and CCR5) and 
concomitantly up-regulate a single known chemokine receptor, C-C chemokine receptor 
type 7 (CCR7) [169], and migrate directed by a gradient of the CCR7 ligands CCL19 and 
CCL21 to the draining lymph nodes [170, 171]. The maturation process is also associated 
with the up-regulation of the co-stimulatory molecules CD40, CD58, CD80, and CD86, 
change in morphology, and changes in the major histocompatibility complex class II (MHC 
class II) compartments [172]. Once in the lymph nodes DCs activate antigen-specific 
lymphocytes (Fig. 3). Besides activating naive T cells, DCs can also directly activate naive 
and memory B cells as well as enhance the differentiation of activated-naive B cells into 
plasma cells [172]. 
 
Figure 3: T cell activation and differentiation induced by DCs. DCs recognize pathogens via 
pathogen recognition receptors (PRRs) including Toll-like receptors and undergo a maturation 
process. Mature DCs express high levels of MHC and co-stimulatory molecules (CD80 and 
CD86), which are needed for efficient activation of naive T cells. TLRs do not only induce 
co-stimulatory molecules, they also contribute to the differentiation into T helper 1 (TH1) 
effector cells by inducing expression of various cytokines, including IL-12. Adapted without 
modifications from Medzhitov, 2001 [129]. 
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In addition to immature and mature differentiation stages, a third stage has been proposed by 
Lutz et al. [173] termed semi-mature or partially mature DCs. This semi-mature state is 
characterized by altered expression levels of surface molecules and a low or absent production 
of pro-inflammatory cytokines such as IL-6, TNF-α, IL-1ß and in particular IL-12 [173]. Such 
semi-mature DCs migrate to lymph nodes but induce tolerance in T cells rather than 
immunity. During infection, induction of semi-mature DCs results in delayed expression of 
immunity and enhanced pathogen survival. In this regard, there is evidence that different 
pathogen-derived components such as the filamentous hemagglutinin (FHA) and the 
adenylate cyclase toxin (CyaA) of Bordetella pertussis as well as the cholera toxin of Vibrio 
cholerae inhibit IL-12 production as well as the CD40 expression of DCs which results in the 
induction of regulatory T cells (Tregs) thereby providing a mechanism to escape protective 
immune responses [174-176]. Figure 4 shows schematically the different pathways of T cell 
activation. 
 
Figure 4: Schematic overview of the mechanisms leading to TH cell or Treg cell activation. 
Mature DCs upregulate cell-surface expression of CD40, CD80, CD86 and MHC class II as 
well as the production of cytokines such as IL-12 or IL-4, leading to TH cell induction. Some 
pathogen-derived molecules activate DCs to a semi-mature or intermediate phenotype by 
stimulation of IL-10 production and inhibition of IL-12 production of DCs, which promotes 
the induction of Treg cells. IL-10 and transforming growth factor-β (TGF-β) produced by 
Treg cells inhibit the activation of TH cells. Adapted with modifications from Mills, 2004 
[177]. 
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The trans-epithelial migration of DCs during normal physiological or inflammatory processes 
requires degradation of extracellular matrices (ECMs), which is largely mediated by the 
production of matrix metalloproteinases (MMPs). The MMP family consists of at least 24 
endopeptidases with common motifs including propeptide and zinc-binding catalytic regions 
(Fig. 5) [178]. Collectively, MMPs are extracellular proteases that are capable of modifying 
almost all components of the extracellular matrix and the basal membrane including 
collagens, fibronectin, elastin, proteoglycans, and laminin [179, 180]. MMP-2 and MMP-9 
(also referred to as gelatinase A and gelatinase B) most specifically cleave gelatin and type IV 
collagen, the major structural components of the ECM [96]. Human MMP-2 is secreted as a 
72-kDa pro-form that is cleaved into a 64-kDa active form; the corresponding pro- and active 
forms of human MMP-9 have masses of 92 kDa and 83 kDa, respectively [181]. MMP-2 is 
known to be produced constitutively by tissue structural cells including fibroblasts and 
endothelial cells, whereas constitutive expression of MMP-9 is restricted to neutrophils [182] 
and eosinophils [183]. Inflammatory stimulation can lead to increased MMP-9 expression in 
many cell types including inflammatory cells such as macrophages [184], eosinophils [185], 
lymphocytes [186], natural killer cells [187], and DCs [188]. Apart from digesting 
components of the ECM, both MMP-2 and MMP-9 have certain chemokines and cytokines as 
their substrates. MMP-2 cleaves the pro-inflammatory molecule monocyte chemoattractant 
protein-3 (MCP-3) into the truncated anti-inflammatory form, which helps in dampening of 
inflammatory processes [189]. MMP-9 has more diverse effects: It degrades α1-antitrypsin, 
protecting neutrophil elastase activity [190], and potentiates the collagenolytic activity of 
MMP-13 [191] and fibroblasts in collagen gels [192]; it increases the chemotactic activity of 
CXCL8 (formerly human IL-8 or murine KC) for neutrophils 10-fold by cleavage of a six-
amino acid peptide from CXCL8, but it also inactivates other neutrophil chemokines [193]. 
MMP-9 is also able to cleave the inactive membrane-bound forms of TNF-α and transforming 
growth factor-beta (TGF-ß) to generate their corresponding active forms [194, 195]. 
Similarly, both gelatinases are able to generate the active form of IL-1ß from its inactive pro-
form [196]. Studies using mice deficient in MMP-9 expression have shown surprising results 
since these mice were protected against cerebral ischemia [197] and traumatic brain injury 
[198] compared to wild-type mice. These data implicate a pathophysiologic role for MMP-9, 
but the precise mechanisms involved remain to be fully elucidated. 
The proteinases are highly regulated at different levels: 1) gene expression and protein 
secretion [199, 200], 2) activation of latent MMP pro-forms by different non-proteolytic 
agents and proteinases [199, 201], and 3) inhibition of activated MMPs. The most important 
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nonspecific inhibitor is α2-macroglobulin [202]. Specific inhibitors of MMPs are the tissue 
inhibitors of matrix metalloproteinases (TIMPs) [203]. TIMP-1 and TIMP-2 are capable of 
inhibiting MMPs by forming stoichiometric 1:1 complexes with active MMPs. 
 
 
Figure 5: Classification of matrix metalloproteinases. On the basis of the domain organization 
the MMPs can be classified into four groups. Adapted without modifications from Overall 
and Otin, 2002 [178]. 
 
There is accumulating evidence supporting an important role for MMPs and TIMPs in a 
variety of pulmonary inflammatory disorders, including asthma [204], chronic obstructive 
pulmonary disease (COPD) [205, 206], acute lung injury [207], acute respiratory distress 
syndrome [208], and pulmonary fibrosis [209]. 
However, scarce information is available regarding the role played by DCs during 
S. pneumoniae infection. In vitro studies have shown that pneumococcal pneumolysin inhibits 
human DC maturation, induction of pro-inflammatory cytokines, and activation of the 
inflammasome [210]. In addition, Noske et al. [211] reported that expression of the 
pneumococcal adherence and virulence factor A (PavA) protected S. pneumoniae against 
recognition and phagocytosis by human DCs. Furthermore, cytokine production was delayed 
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and reduced when DCs were exposed to S. pneumoniae deficient in the expression of PavA 
[211]. The interactions between S. pneumoniae and DCs during in vivo infections has, 
however, not been investigated so far. 
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2. Aim of the study 
S. pneumoniae is still a major cause of community-acquired infections of the respiratory tract, 
central nervous system and bloodstream. It is associated with significant morbidity and 
mortality, and poses a major economic burden to the healthcare system. The global 
emergence of antibiotic-resistant pneumococcal strains has complicated treatment decisions 
and increased the likelihood of treatment failure. More detailed understanding of the 
interactions between S. pneumoniae and the host may open up new avenues for the 
development of more effective treatment regimens, targeting not solely bacterial destruction, 
but also modulation of the host response. 
Dendritic cells are potent antigen-presenting cells able to initiate and regulate innate and 
adaptive immune responses against invading pathogens. In the lung, dendritic cells are 
situated in immediate proximity to the respiratory epithelial cells, where they form an 
elaborate network that rapidly reacts to incoming pathogens. Despite the clinical relevance of 
pneumococcal pneumonia, scarce information is available regarding the role played by 
dendritic cells during this infection. Therefore, the aim of this study was to investigate the 
role of dendritic cells in the host response to S. pneumoniae lung infections. 
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3. Materials & Methods 
3.1. Materials  
3.1.1. Chemicals, solutions and kits  
Table 1: Chemicals, solutions, kits and their suppliers used in this study. 
Chemical / Solution / Kit  Company  
2-Mercaptoethanol, 50 mM  Invitrogen, Karlsruhe, Germany  
3,8-diamino-5-ethyl-6-
phenylphenantridiniumbromide  
(Ethidium Bromide)  
Sigma Aldrich, Munich, Germany  
 
Agarose NEEO Ultra quality Carl Roth, Karlsruhe, Germany 
Albumine, IgG free Carl Roth, Karlsruhe, Germany 
Ammonium chloride (NH4Cl) Merck, Darmstadt, Germany 
Aprotinin Sigma Aldrich, Munich, Germany 
BactoTM yeast extract BD PharmingenTM, Heidelberg, Germany 
BD Columbia Agar with 5% Sheep Blood BD PharmingenTM, Heidelberg, Germany 
Brij-35 (30% v/v) Merck, Darmstadt, Germany 
Bromophenol blue Sigma Aldrich, Munich, Germany 
Carrageenan type IVλ Sigma Aldrich, Munich, Germany 
Collagenase Type F Sigma Aldrich, Munich, Germany 
Coomassie Brilliant Blue G-250 
 
Serva Electrophoresis GmbH, Heidelberg, 
Germany 
Deoxyribonuclease I (DNase I) Qiagen, Hilden, Germany 
Dimethyl sulfoxide (DMSO) Sigma Aldrich, Munich, Germany 
Diphtheria Toxin (DT) Sigma Aldrich, Munich, Germany 
Disodium hydrogen phosphate dihydrate 
(Na2HPO4·2H2O) 
AppliChem, Darmstadt, Germany 
 
Erythromycin Sigma Aldrich, Munich, Germany 
Ethanol, 96% (v/v) J.T. Baker, Deventer, Netherlands 
Ethylenediaminetetraacetic acid (EDTA) AppliChem, Darmstadt, Germany 
Evans Blue Sigma Aldrich, Munich, Germany 
Fetal calf serum (FCS) 
Gelatin (bovine) 
Biochrom, Berlin, Germany 
Sigma Aldrich, Munich, Germany 
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GeneRulerTM DNA ladder mix,  
100-10,000 bp 
Fermentas, St. Leon-Rot, Germany 
Gentamicin Sigma Aldrich, Munich, Germany 
Glycerine 86%, p.a. Carl Roth, Karlsruhe, Germany 
Hydrochloric acid (HCl), 37% Carl Roth, Karlsruhe, Germany 
Kanamycin Carl Roth, Karlsruhe, Germany 
Leupeptide Sigma Aldrich, Munich, Germany 
L-Glutamine (200 mM) PAA Laboratories, Pasching, Austria 
Lipopolysaccharide (LPS) of E.coli Sigma Aldrich, Munich, Germany 
Maxima™ SYBR Green qPCR Master Mix 
(2 ×) 
Thermo Scientific, Bonn, Germany  
M-MLV Reverse Transcriptase Kit Promega, Mannheim, Germany 
Nuclease-free water Applied Biosystems/Ambion, TX, USA 
OptiPrepTM density gradient Axis-Shield, Heidelberg, Germany 
Penicillin/Streptomycin, 100 × PAA Laboratories, Pasching, Austria 
Phenylmethyl sulfonyl fluoride (PMSF) AppliChem, Darmstadt, Germany  
Polyoxyethylene Sorbitan Monolaurate 
(Tween-20) 
Serva Electrophoresis GmbH, Heidelberg, 
Germany 
Potassium chloride (KCl) Carl Roth, Karlsruhe, Germany 
RNeasy Mini Kit Qiagen, Hilden, Germany 
RNeasy Midi Kit Qiagen, Hilden, Germany 
RPMI 1640 Invitrogen, Karlsruhe, Germany 
RevertAid First Strand cDNA synthesis Kit Thermo Scientific, Bonn, Germany 
Sodium carbonate (Na2CO3) Merck, Darmstadt, Germany 
Sodium chloride (NaCl) Carl Roth, Karlsruhe, Germany 
Sodium hydroxide (NaOH) Carl Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate (SDS) Sigma Aldrich, Munich, Germany 
Sulfuric acid (H2SO4) Carl Roth, Karlsruhe, Germany 
Todd-Hewitt Broth Sigma Aldrich, Munich, Germany 
Triton X-100 Carl Roth, Karlsruhe, Germany 
Trizma® Base, ≥99.9% Sigma Aldrich, Munich, Germany 
Tryphan blue (0.4%) Sigma Aldrich, Munich, Germany 
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3.1.2. Antibodies 
Table 2: Antibodies and their suppliers used in this study. 
Antibody Company 
Anti-mouse CD4-FITC Invitrogen, Darmstadt, Germany 
Anti-mouse CD8a-PE Invitrogen, Darmstadt, Germany 
Anti-mouse CD11b-APC Invitrogen, Darmstadt, Germany 
Anti-mouse CD11c-PE Invitrogen, Darmstadt, Germany 
Anti-mouse CD40-FITC Invitrogen, Darmstadt, Germany  
Anti-mouse CD80-FITC  Invitrogen, Darmstadt, Germany  
Anti-mouse CD86-FITC  Invitrogen, Darmstadt, Germany  
Anti-mouse CCR7-APC Invitrogen, Darmstadt, Germany 
Anti-mouse MHC class II-PE  Invitrogen, Darmstadt, Germany 
Anti-mouse Ly6G-PE Invitrogen, Darmstadt, Germany 
BD OptEIATM Mouse ELISA Kit 
(IL-6, IL-12, TNF-α) 
BD PE annexin V apoptosis detection kit I 
BD PharmingenTM, Heidelberg, Germany  
 
BD PharmingenTM, Heidelberg, Germany 
 
3.1.3. Buffers & media  
Table 3: Composition and preparation of buffers and media. 
Buffer / Medium  Amount of chemical / solution  
0.05% Tween/PBS (5 L)  250 mL 20 × PBS, pH 7.4  
2.5 mL Tween® 20  
ad 5 L Aq. dest.  
0.5 µg/mL Ethidium Bromide (1 L)  800 µl Ethidium Bromide  
ad 1 L Aq. dest.  
0.5 M EDTA, pH 8.0 (1 L)  186.12 g EDTA Na2·2H2O  
ad 1 L Aq. dest.  
adjust pH 8 with NaOH  
1 M HCl (100 mL)  8.4 mL 37% HCl  
ad 100 mL Aq. dest.  
1 M NaOH (100 mL)  4 g NaOH  
ad 100 mL Aq. dest.  
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1 M Tris, pH 8.8 (1 L)  121.1 g Trizma Base  
ad 1 L Aq. dest.  
adjust pH 8.8 with HCl  
1% agarose gel (100 mL) 
 
1 g agarose 
100 mL 1 M Tris, pH 8.8 
Boil in microwave until agarose is melted 
100 mM Na2CO3, pH 9.6 (1L) 
 
10.6 g Na2CO3 
ad 1 L Aq. dest. 
adjust pH 9.6 with HCl 
1 × PBS, pH 7.4 (1 L) 
 
50 mL 20 × PBS, pH 7.4 
ad 1 L Aq. dest., autoclave 
1 × TAE, pH 8.5 (1L) 
 
20 mL 50 × TAE 
ad 1 L Aq. Dest. 
20 × PBS, pH 7.4 (1 L) 
 
 
 
 
 
160 g NaCl 
4 g KCl 
15.2 g Na2HPO4·2H2O 
4 g KH2PO4 
ad 1 L Aq. dest. 
adjust pH 7.4 with NaOH 
50 × TAE, pH 8.5 (1 L) 
 
 
 
242 g Trizma Base 
57.1 mL Acetic Acid 
100 mL of 0.5 M EDTA, pH 8.0 
ad 1 L Aq. dest. 
Ammonium-Chloride-Potassium buffer  
(ACK buffer) (1 L) 
 
 
1.0 g KHCO3  
8.29 g NH4Cl  
37.22 mg EDTA  
Na2·2H2O 
ad 1 L Aq. dest. 
adjust pH 7.4 with HCl 
filter-sterilize (ø 0.22 µm),  
store at room temperature (RT) 
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Ketamin-Rompun (anesthetic) 
 
1 mL 10% Ketamin  
8.5 mL 0.9% NaCl  
0.5 mL 2% Rompun 
Inject 0.1 mL/10g body weight i.p. 
Lysis buffer, pH 7.4 (1 L) 
 
11.69 g NaCl 
1.86 g EDTA Na2·2H2O 
1.211g Trizma Base 
100 mL glycerol 
10 mL 0.1 M PMSF 
1 mg leupeptide 
28 mg aprotinin 
ad 1 L Aq. dest. 
adjust pH 7.4 with NaOH, store at -20°C 
RPMI complete medium (500 mL) 
 
50 mL FCS 
5 mL Penicillin/Streptomycin (1%) 
5 mL 200 mM L-Glutamine 
THY-Medium (1 L) 
 
30 g Todd-Hewitt-Broth 
10 g Yeast extract 
ad 1 L Aq. dest. and autoclave 
Zymography separating gel (10%) 
(adequate for 2 × 75mm gels) 
 
3 mL ddH2O  
2.36 mL 1.5M Tris, pH 8.8  
90 µL 10% SDS  
3 mL 30% Acryl/bis-acryl 
600 µL gelatin (15mg/mL) 
4.4 µL TEMED 
44 µL APS (100mg/mL)  
Zymography stacking gel (4%) 
(adequate for 2 × 75mm gels) 
 
3.71 mL ddH2O  
550 µL 0.5M Tris, pH 6.8  
50 µL 10% SDS  
675 µL 30% Acryl/bis-acryl  
7.5 µL TEMED  
30 µL APS (100mg/mL) 
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Zymogrography 2 × SDS Sample Buffer  
(8 mL) 
 
1.0 mL 0.5 M Tris-HCl, pH 6.8 
0.8 mL glycerol 
1.6 mL 10% (w/v) SDS 
0.2 mL 0.5% (w/v) bromophenol blue 
ad 8 mL Aq. dest. 
Zymography 4 × Tank Buffer (1 L) 
 
15.0 g Trisma Base 
72.0 g glycine 
5.0 g SDS 
ad 1 L Aq. dest. 
Store at 4 ºC, warm to 37 ºC before use if a 
precipitate forms. Use 1 × Tank buffer for 
electrophoresis. 
Zymography 10 × LSCB (1 L) 
 
60.55 g Trisma Base (pH 7.6) 
116.88 g NaCl  
5.54 g CaCl2  
0.2% (w/v) Brij-35 
ad 1 L Aq. dest. 
Zymography Coomassie Brilliant Blue  
G-250 (1 L) 
62.5 mL 1.0% stock Coomassie G-250  
250 mL methanol 
50 mL 10% acetic acid 
20 mM EDTA 
ad 1 L Aq. dest. 
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3.1.4. Materials & Instruments 
Table 4: Materials, instruments and their manufacturer used in this study. 
                              Instrument  Company  
Centrifugation     Centrifuge 5804R  Eppendorf, Hamburg, Germany  
                              Centrifuge 5417R  Eppendorf, Hamburg, Germany  
Photometry          BDTM LSRII Analyzer  BD Biosciences, CA, USA  
                              FACSCaliburTM flow cytometer  BD Biosciences, CA, USA  
                              Kodak Image Station 2000R  Kodak, NY, USA  
                              LightCycler® 480 Real-Time  
                              PCR System  
Roche Diagnostics Deutschland 
GmbH, Mannheim, Germany  
                              Multitron Standard  Infors HT, Einsbach, Germany  
                              NanoDrop® 2000c  Thermo Fisher Scientific, IL, USA  
                              NOVASPEC II                                 Pharmacia LKB, Uppsala, Sweden 
                              SunriseTM                                          Tecan Group Ltd., Männedorf, 
Switzerland 
                              96-Well ELISA Microtiter plates,  
                              U bottom, clear  
Greiner Bio-One Ltd, Stonehouse, 
United Kingdom  
Medical device    BD MicrolanceTM 25G  
                              BD MicrolanceTM 26G 1/2  
BD Biosciences, CA, USA  
BD Biosciences, CA, USA  
                              Inject® Solo (5 mL syringe)  Braun, Melsungen, Germany  
                              Omican®-F (1 mL syringe  
                              int. needle)  
Braun, Melsungen, Germany  
                              Omnifix®-F Solo (1 mL syringe)  Braun, Melsungen, Germany  
Cell culture          BD FalconTM cell strainer  
                              (ø 100 µm)  
BD Biosciences, CA, USA  
                              BX51 microscope  Olympus, Hamburg, Germany  
                              CellTrics® (ø 30 µm)  Partec, Münster, Germany  
                              GFL 1003 water bath  Gesellschaft für Labortechnik mbH, 
Burgwedel, Germany  
                              HERAcell 150i CO2 incubator  Thermo Fisher Scientific, IL, USA  
                              Hemacytometer (Neubauer) 
 
Marienfeld GmbH, Marienfeld, 
Germany  
                              TPP 96-well tissue culture plate Sigma Aldrich, Munich, Germany 
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                             Wallac MicroBeta® TriLux Perkin Elmer/ Wallac, Freiburg, 
Germany 
                              96-Well ELISA Microtiter plates,  
                              F bottom, clear 
Greiner Bio-One Ltd, Stonehouse, 
United Kingdom 
Other                    BRL Horizon®58  
                              electrophoresis chamber 
Invitrogen, Karlsruhe, Germany 
 
                              Dispersing aggregate PT-DA  
                              2112/2 WEC 
KINEMATICA AG, Lucerne, 
Switzerland 
                              Electrophoresis power supply 
                              ST606T 
Invitrogen, Karlsruhe, Germany 
                              Eppendorf Research® 
                              PhysioCare Concept pipettes 
Eppendorf, Hamburg, Germany 
 
                              Immuno 96 MicroWellTM Solid 
                              Plates 
Thermo Fisher Scientific, IL, USA 
 
                              Millex® syringe filter units  
                              (ø 0.22 µm) 
Sigma Aldrich, Munich, Germany  
                              MS2 minishaker IKA, Staufen, Germany 
                              POLYTRON PT 2100 
                              homogenizer 
KINEMATICA AG, Lucerne, 
Switzerland 
                              ThermostatTM 5320 Eppendorf, Hamburg, Germany 
                              Tpersonal Thermocycler Biometra, Göttingen, Germany 
 
3.2. Methods 
3.2.1. Bacterial strains and growth conditions 
The S. pneumoniae strains D39 capsular serotype 2 [212] and S. pneumoniae serotype 4, 
strain TIGR4 [213] were grown at 37°C in Todd-Hewitt broth supplemented with 1% (w/v) 
yeast extract (THY-medium) and 10% of heat-inactivated fetal calf serum (FCS). The 
pneumolysin-deficient mutant strain D39∆ply [56] was grown in the presence of 12.5 µg/mL 
erythromycin. Bacteria were grown to the mid-log phase (OD600 ≈ 0.4), collected by 
centrifugation for 10 minutes at 4000 rpm, and washed twice with sterile PBS. For 
preparation of the inoculum, the bacterial suspension was diluted with PBS to the required 
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concentration and the number of viable cells determined after serial dilution and plating onto 
blood agar. 
 
3.2.2. Mouse strains 
BALB/c mice were purchased from Harlan-Winkelmann (Borchen, Germany), B6.FVB-Tg 
[Itgax-DTR/GFP] 57Lan/J (referred to as CD11c-DTR) transgenic mice [214] were obtained 
from Steffen Jung (The Weizmann Institute of Science, Rehovot, Israel) and backcrossed 
against the BALB/c background. These transgenic mice express a simian diphtheria toxin 
(DT) receptor under the control of the murine CD11c promoter region. Since the simian 
receptor is 103-105 times more susceptible to DT than the murine DT-receptor (DTR) [215] 
this allows selective depletion of DCs following the administration of DT because all murine 
DC subsets express CD11c on the surface (Fig. 6). 
 
Figure 6: Depletion of DCs in CD11c-DTR mice. DCs of wild-type (wt) mice express the 
murine DTR with a low affinity to DT, whereas DCs of the transgenic CD11c-DTR mice 
express the high-affinity simian DTR. DT binds specifically to the simian DTR via the B 
subunit, that facilitates entry of the A subunit into the cell. The A subunit of DT inactivates 
elongation factor 2 through ADP ribosylation, thereby preventing protein synthesis and 
causing cell death. Adapted without modifications from Bennett and Clausen, 2007 [215]. 
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Since one dose of DT is not enough to deplete DCs in the lungs and repeated administration 
has been shown to be lethal to CD11c-DTR mice, bone marrow chimera mice were generated 
as previously described [216]. Briefly, 2.5 × 105 bone marrow cells from CD11c-DTR donor 
mice were transferred intravenously into BALB/c mice, which were lethally irradiated (950 
rads) 24 h earlier. The chimeric animals (referred to as CD11c-DTR chimera mice) were 
housed in individually ventilated pathogen-free cages and treated for 1 week with 0.04% 
Baytril together with 0.054% glucose in their drinking water. The CD11c-DTR chimeras were 
ready for experimental use 8 weeks after reconstitution. For continuous depletion of DCs, 
CD11c-DTR chimera mice received a daily intraperitoneal injection of DT (8 ng/g body 
weight in 200 µL PBS) starting two days before infection. DT treatment effectively depleted 
DCs from the lungs of CD11c-DTR chimera mice for up to 4 days (Fig. 7). 
 
 
 
Figure 7: DC depletion efficiency in the lungs of CD11c-DTR chimera mice after treatment 
with consecutive doses of DT. CD11c-DTR chimera mice were injected with 1, 2, 3 or 4 
successive doses of DT (8 ng/g body weight) or PBS. Lungs were digested and transformed 
into single cell suspensions 24 h after treatment and stained with anti-mouse CD11c 
antibodies for flow cytometry analysis. (A) Representative histogram of CD11c expression on 
lung cells of PBS-treated or DT-treated CD11c-DTR chimera mice. (B) Percentage of 
CD11c+ cells in the lungs of PBS-treated or DT-treated CD11c-DTR chimera mice. 
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3.2.3. Double depletion of DCs and neutrophils 
CD11c-DTR chimera mice were injected intraperitoneally daily with DT (8 ng/g body weight 
in 200 µL PBS) or with 200 µL of sterile PBS starting two days before infection and injected 
intravenously with 100 µg of anti-mouse RB6 antibody one day before bacterial inoculation. 
Control mice received equivalent amounts of isotype control antibodies in sterile PBS. The 
efficiency of neutrophil depletion was verified by flow cytometric analysis of peripheral 
blood obtained by retro-orbital bleeding of mice prior to and two days after anti-mouse RB6 
antibody or mock treatment (Fig. 8). Briefly, blood was taken with a microhematocrit 
capillary tube and collected in a tube containing 300 µL with 2 U/mL heparin in 1 × PBS. The 
blood was centrifuged at 600 × g for 3 min at room temperature (RT) and the supernatant was 
discarded. While vortexing the cells, 9 mL of deionised water was added followed by 3 mL of 
4 × PBS to lyse the erythrocytes. The cell suspension was further centrifuged, the pellet 
resuspended in 1 × PBS and the cells stained with PE-conjugated anti-mouse Ly6G antibodies 
for flow cytometry analysis. 
 
 
Figure 8: Neutrophil depletion efficiency in CD11c-DTR chimera mice after anti-mouse RB6 
treatment. CD11c-DTR chimeras were depleted of neutrophils by intravenous injection of 
100 µg purified anti-mouse RB6. Neutrophils of the blood were stained with PE-conjugated 
anti-mouse Ly6G for flow cytometry analysis. Representative histograms of Ly6G-positive 
neutrophils in the blood of a CD11c-DTR chimera mouse before (A) and 48 h after treatment 
with anti-mouse RB6 antibodies (B). 
 
3.2.4. Infection model of pneumococcal pneumonia 
For intranasal infection with S. pneumoniae, mice were anesthetized by intraperitoneal 
injection with ketamine-rompun solution (see Tab. 3) and inoculated intranasally with 1 × 108 
CFU (colony forming units) of S. pneumoniae. At specified time points after bacterial 
inoculation, mice were euthanized by CO2 asphyxiation, the organs were aseptically collected 
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and bacterial burdens were determined by preparing homogenates in 5 mL PBS and plating 
10-fold serial dilutions on blood agar. Colonies were counted after overnight incubation at 
37°C. For collection of serum, blood was collected at time of sacrifice, centrifuged at 5000 
rpm for 10 min, and frozen at -80°C until use for further analysis. 
All animal experiments were performed in strict accordance with the German regulations of 
the Society for Laboratory Animal Science (GV-SOLAS) and the European Health Law of 
the Federation of Laboratory Animal Science Associations (FELASA). All experiments were 
approved by the ethical board Niedersächsisches Landesamt für Verbraucherschutz und 
Lebensmittelsicherheit, Oldenburg in Germany (Permit No. 33.11.42502-04-118/08). 
 
3.2.5. Detection of cytokines and chemokines  
Cytokines/chemokines were analyzed either by ELISA (enzyme-linked immunosorbent assay) 
according to the recommendations of the manufacturer using matched antibody pairs and 
recombinant cytokines as standards or by multiplex bead technology according to the 
manufacturer’s protocol. Briefly, for ELISA 96-well microtiter plates were coated with the 
purified anti-mouse capture antibody targeting the respective cytokine and incubated 
overnight at 4°C. The wells were washed with 0.05% Tween/PBS and then blocked with 200 
µL of 10% FCS in PBS for 1 h at RT before samples and the appropriate standard (100 
µL/well) were added. After incubation for 2 h at RT, the wells were washed again and the 
matching biotinylated anti-mouse detection antibody was applied. Detection was carried out 
with Streptavidin-horseradish peroxidase conjugated secondary antibody and the plates 
developed using TMB (100 µL/well) as substrate. The reaction was stopped by the addition of 
2N H2SO4 solution (50 µL/well). The absorbance was read at 450 nm versus 570 nm using the 
Sunrise absorbance reader and MagellanTM3 software. The background signal obtained from 
wells incubated with only assay buffer was subtracted before the cytokine concentrations 
were calculated based on the standard curve generated using recombinant cytokines. Samples 
and standards were at least measured in duplicates. 
For determination of cytokine levels in lung tissue, lungs were homogenized in 1.5 mL lysis 
buffer (see Tab. 3) with a tissue grinder. Homogenized lung supernatants were collected by 
centrifugation at 13000 rpm for 10 min at 4°C, aliquoted and stored at -80°C until use for 
further analysis. 
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3.2.6. Isolation of lung cells for flow cytometry analysis 
For analysis of immune cells recruited into the lungs during infection, the lungs were 
shredded into small pieces and enzymatically digested with 1 mg/mL of collagenase F and 
50 U of DNase I in 500 µL RPMI 1640 at 37°C and 5% CO2 for 30 min. The reaction was 
stopped by adding 1 mL of 10 mM EDTA (see Tab. 3) followed by incubation for 10 min on 
ice. The resulting tissue/cell suspension was filtered through a 100-µm strainer, centrifuged at 
900 rpm for 8 min and the red blood cells lysed by adding 3 mL of ACK buffer (see Tab. 3) to 
the pellet. The cell suspension was centrifuged for 10 min at 900 rpm, resuspended in 1 mL 
RPMI 1640, counted and stained for flow cytometry analysis.  
Cells were incubated for 5 min with 0.5 µL purified rat anti-mouse CD32/CD16 antibodies to 
block the Fc receptors, followed by incubation either with FITC-conjugated anti-mouse CD4, 
PE-conjugated anti-mouse CD8a, PE-conjugated anti-mouse CD11c, APC-conjugated anti-
mouse CD11b, PE-conjugated anti-mouse Ly6G alone or in combination. After incubation for 
30 min at 4°C, cells were washed and flow cytometry analysis was performed using the BDTM 
LSR II flow cytometer. 
 
3.2.7. Gentamicin protection assay 
To determine the amount of intracellular S. pneumoniae within lymph node cells, mediastinal 
lymph nodes were taken at 24 and 48 h after bacterial inoculation from S. pneumoniae-
infected BALB/c mice. A single cell suspension was generated by carefully grinding the 
lymph nodes through a nylon sieve (ø 100 µm) with the back of a plunger. The cells were 
centrifuged at 900 rpm for 8 min and the supernatant plated in 10-fold serial dilutions onto 
blood agar plates to determine the number of extracellular bacteria. The cells were incubated 
with 200 µL ACK buffer for 2 min at room temperature to lyse the erythrocytes. The 
procedure was stopped by adding 400 µL 1 × PBS and subsequent centrifugation at 900 rpm. 
To eliminate any extracellular bacteria, the cell pellet was treated with gentamicin (100 
µg/mL) for 2 h and afterwards collected by centrifugation. The cell pellet was disrupted after 
treatment with 50 µL ddH2O, and the amount of viable intracellular bacteria was determined 
after serial plating onto blood agar. 
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3.2.8. Generation of bone marrow-derived dendritic cells 
BALB/c mice were sacrificed by CO2 asphyxiation and bone marrow cells were flushed from 
both femurs and tibias. Progenitor cells were resuspended, adjusted to a concentration of 1 × 
106/mL and cultured for 6-8 days at 37°C and 5% CO2 in RPMI 1640 with 5% FCS, 1% 
penicillin/streptomycin, 50 ng/mL of recombinant mouse GM-CSF (granulocyte-macrophage 
colony-stimulating factor), and 10 ng/mL IL-4 (interleukin 4). DCs were gently washed (900 
rpm) and fed with fresh medium supplemented with GM-CSF and IL-4 on day 2 and 5. On 
day 7, the DC fraction was enriched using an OptiPrepTM gradient according to the 
manufacturer’s instructions. The purity of the resulting cell population consisted of >80% of 
DCs as determined by flow cytometry analysis using PE-conjugated anti-mouse CD11c 
antibodies. 
 
3.2.9. In vitro infection of bone marrow-derived DCs 
Bone marrow-derived DCs were seeded in 48-well plates at a density of 5 × 106/mL and 
infected with S. pneumoniae at a multiplicity of infection (MOI) of 20 bacteria per DC unless 
otherwise noted. Infected DCs were incubated for 90 min in antibiotic-free RPMI medium, 
washed twice with sterile 1 × PBS to remove unbound bacteria and further incubated in RPMI 
1640 supplemented with 5% FCS, 100 µg/mL of gentamicin and 10 µg/mL of penicillin. 
Stimulation with 1 µg/mL lipopolysaccharide (LPS) of Escherichia coli was used as a 
positive control for flow cytometry analysis of maturation markers and cytokine production. 
DCs were collected by centrifugation 24 h after infection, washed with 1 × PBS and stained 
for flow cytometry analysis. Antibodies used for the flow cytometry analysis of maturation 
markers were: PE-conjugated anti-mouse CD11c, FITC-conjugated anti-mouse CD40, FITC-
conjugated anti-mouse CD80, FITC-conjugated anti-mouse CD86, FITC-conjugated anti-
mouse MHC-II and APC-conjugated anti-mouse CCR7. Culture supernatant was also 
collected and stored at -80°C for later determination of cytokine concentration and gelatin gel 
zymography. 
 
3.2.10. DC viability test 
Viability of DCs during in vitro studies was determined using the PE Annexin V apoptosis 
detection kit I. Therefore, bone marrow-derived DCs were harvested by centrifugation (900 
rpm, 8 min), washed twice with cold 1 × PBS and resuspended in 1 × binding buffer at a 
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concentration of 1 × 106/mL. 100 µL of the solution (containing 1 × 105 cells) were 
transferred to a 5 mL tube and stained with 5 µL PE Annexin V and 5 µL 7-AAD. The cells 
were gently vortexed and incubated for 15 min at RT in the dark. After adding 400 µL of 1 × 
binding buffer the cells were analyzed by flow cytometry. 
 
3.2.11. Analysis of gene expression 
Real-time quantitative RT-PCR was performed to measure the mRNA expression levels of 
mmp-9 gene. Total RNA was extracted from cultured DCs using an RNeasy Mini Kit and 
from lung tissue using an RNeasy Midi Kit according to the manufacturer’s 
recommendations. RNA was reverse transcribed and cDNA synthesis performed using the 
RevertAidTM First Strand cDNA synthesis kit. PCR amplification was performed using the 
LightCycler 480 Real-Time PCR system with the Maxima SYBR Green qPCR Master Mix. 
RT-PCR was performed in a 20 µl-volume reaction containing 5 µL cDNA, 2 µL specific 
primer mix (10 pmol), and 10 µL 2 × conc. Mastermix (SYBR Green qPCR). Thermal 
cycling consisted of denaturation for 10 min at 95° C followed by 50 cycles of 30 sec at 95°C, 
30 sec at 59°C and 45 sec at 72°C. The sequence for MMP-9 sense primer was: 5'-
GGGAAGGCTCTGCTGTTCAGC-3', and for antisense primer: 5'-
TCTAGAGACTTGCACTGCACG-3'. The sequence for ß-actin sense primer was: 5'-
TGGAATCCTGTGGCATCCATGAAA-3' and antisense primer: 5'-
TAAAACGCAGCTCAGTAACAGTCCG-3'. Cycle threshold values for MMP-9 were 
normalized to the housekeeping gene β-actin. The data were calculated using the Pfaffl 
equation [217] and expressed as a ratio of the relative mRNA expression in infected samples 
to that in uninfected controls. 
 
3.2.12. Gelatin gel zymography 
Enzymatic activity of MMP-9 in culture supernatants of bone marrow-derived DCs was 
determined by SDS-PAGE gelatin gel zymography. Gelatinases like MMP-9 degrade the 
gelatin matrix in the gel, leaving a clear band after staining the gel for protein [218]. Culture 
supernatant of pneumococcal infected and uninfected bone marrow-derived DCs were taken 6 
and 24 h after infection, the protein concentrations determined using the Bradford method 
[219], and the samples mixed with equal volumes of 2 × SDS sample buffer (see Tab. 3). The 
samples were electrophoresed in 10% SDS-PAGE containing 0.1% (w/v) bovine gelatin. Gels 
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were incubated with gentle agitation in renaturing buffer (2.5% Triton X-100) at RT for 20 
min and then incubated for at least 72h at 37°C in 1 × LSCB buffer containing 5 mM CaCl2, 
0.2 M NaCl, 0.02% (w/v) Brij-35, and 50 mM Tris (pH 7.6). Thereafter, gels were stained 1 h 
with Coomassie Dye containing 0.06% Coomassie Brilliant Dye G, 25% (v/v) methanol, 
0.005% acidic acid, and 20mM EDTA. After destaining with 10% acidic acid, gels were 
imaged on a Cano Scan 9000F. 
 
3.2.13. In vivo vascular permeability assay 
Bone marrow-derived DCs were cultured at a density of 5 × 105/mL in antibiotic-free RPMI 
1640 and infected with S. pneumoniae at a MOI of 10 bacteria per DC for 90 min. Bone 
marrow-derived DCs were then washed and further incubated in the presence of antibiotics 
(100 µg/mL gentamicin, 10 µg/mL penicillin) at 37°C and 5% CO2. The culture supernatant 
was collected after 24 h of culture and stored at -80°C until use. Medium from uninfected 
DCs as well as medium where only bacteria were added were used as control. Evans blue 
(30mg/kg body weight) was injected intravenously into BALB/c mice, and the mice were 
subsequently anesthetized and the dorsal skin carefully shaved. 50 µL of the supernatant was 
injected intradermally into the dorsal skin of the mice. 1 h later the mice were sacrificed, 
pictures of the injection site were taken from the basal site of the skin and the size of the 
Evans blue spots measured before they were resected. For quantification of the vascular 
leakage the Evans blue was extracted by incubation of the tissue in 500 µL of formamide at 
60°C for 48 h and subsequently analyzed by spectrophotometry at 620 nm using the Sunrise 
absorbance reader and MagellanTM3 software. For the generation of a standard Evans blue 
solution was diluted 10-fold in formamide. 
 
3.2.14. Statistical analysis  
All data were analyzed in Microsoft Excel 2007 or GraphPad Prism 5.0 (GraphPad Software, 
San Diego, CA). Unless otherwise specified, results are presented as the mean ± SD. 
Comparison between groups was performed by the use of a two-tailed t-test or one-way 
ANOVA. P values ≤ 0.05 were considered as significant.  
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4. Results 
4.1. Depletion of DCs results in enhanced resistance to S. pneumoniae infection 
To determine the importance of DCs in host defense against S. pneumoniae, a CD11c-DTR 
transgenic mouse line that permits conditional transient depletion of DCs by administration of 
DT was used. In these mice, DCs can be specifically depleted since CD11c+ cells (which are 
DCs and alveolar macrophages) express the simian DTR on their surface. This receptor is 
1000 times more susceptible to DT than the murine receptor. Endocytosis of DT after binding 
via its B subunit to the simian DTR results in protease-mediated splitting of the A and B 
subunits. The subunit B forms pores in the endosome membrane, thereby facilitating the 
release of the A subunit into the cytoplasm of the cell. The A subunit catalyzes the ADP-
ribosylation of elongation factor 2 (EF-2). Since EF-2 is needed for the moving of tRNA from 
the A-site to the P-site of the ribosome during protein translation, ADP-ribosylation of EF-2 
inhibits protein synthesis and thereby causes cell death [220]. 
Generally, CD11c-DTR mice allow depletion of DCs only for two days, and do not survive a 
second diphtheria toxin injection [214]. To enable prolonged depletion of DCs by multiple 
DT treatments, bone marrow chimeras were generated by transferring bone marrow from 
CD11c-DTR mice into lethally irradiated BALB/c mice as previously described [221]. 
CD11c-DTR chimera mice were depleted of DCs and infected intranasally with a sublethal 
inoculum of S. pneumoniae strain D39 (1 × 108 CFU). Bacterial loads were monitored in the 
lungs, mediastinal lymph nodes, blood and spleen at 24, 48 and 72 h after bacterial 
inoculation. 
Depletion of DCs rendered CD11c-DTR chimera mice significantly more resistant to 
infection with S. pneumoniae than non-depleted animals. Thus, depletion of DCs significantly 
reduced the amount of S. pneumoniae recovered from the lungs of infected mice at 48 and 
72 h of infection (Fig. 9A). S. pneumoniae disseminated from the lungs first to the mediastinal 
lymph nodes and then to the blood and the systemic organs as shown by the detection of 
pneumococci in the lymph nodes at 24 h of infection as well as in the blood and the spleen at 
48 h after bacterial inoculation (Fig. 9B-9D). Furthermore, S. pneumoniae disseminated to the 
lymph nodes to a lesser extent in DC-depleted than in non-depleted CD11c-DTR chimera 
mice (Fig. 9B).  
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Figure 9: Bacterial burdens in the organs of DC-depleted and non-depleted mice after 
respiratory challenge with S. pneumoniae. DC-depleted (white symbols) and non-depleted 
(black symbols) CD11c-DTR chimera mice were intranasally inoculated with 1 × 108 CFU of 
S. pneumoniae D39 and the bacterial loads determined in the lungs (A), mediastinal lymph 
nodes (B), blood (C) and spleen (D) at progressive time points after bacterial inoculation. 
Each symbol represents an individual animal. Horizontal solid lines indicate the mean value 
of non-depleted mice, whereas broken lines designate the mean value of DC-depleted 
animals. One representative experiment out of three is shown. *, p < 0.05 and **, p < 0.01. 
 
It has been reported that treatment of CD11c-DTR mice with DT can result in the depletion of 
alveolar macrophages in addition to DCs [222]. However, it has been reported that in vivo 
depletion of alveolar macrophages alone via intranasal instillation of liposomal 
dichloromethylene-bisphosphonate before infection with S. pneumoniae does not affect the 
bacterial burdens in the lungs or blood of infected mice although it significantly increased the 
mortality of infected animals [145]. Therefore, the benefit conferred by the depletion of 
CD11c+ cells on the course of S. pneumoniae infection can be attributed to the depletion of 
DCs rather than the depletion of alveolar macrophages. 
To determine if the beneficial effect of DC-depletion in CD11c-DTR chimera mice is strain 
specific, the DC-depleted and non-depleted mice were intranasally inoculated with the 
S. pneumoniae strain TIGR4. This strain is encapsulated and has been shown to be highly 
invasive and virulent in mice [213]. Inoculation of BALB/c mice with a dose of 
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S. pneumoniae strain TIGR4 similar to that used for infections with strain D39 (1 × 108 CFU) 
resulted in enhanced mortality starting 24 h after bacterial inoculation (data not shown). These 
results demonstrated the superior virulence of S. pneumoniae TIGR4 compared to 
S. pneumoniae strain D39. Therefore, CD11c-DTR chimera mice were infected with a lower 
dose of S. pneumoniae TIGR4 (1 × 107 CFU) which resulted in significantly reduced amounts 
of bacteria in the mediastinal lymph nodes, blood and spleen at 24 h of infection in DC-
depleted mice compared to non-depleted animals (Fig. 10). Similar to infection with 
S. pneumoniae D39 there was no difference in the bacterial loads in the lungs at this time of 
infection. These results indicate that the increased resistance of DC-depleted CD11c-DTR 
chimera mice to pneumococcal pneumonia was not strain specific. 
 
 
Figure 10: Bacterial burdens in the organs of DC-depleted and non-depleted mice after 
intranasal infection with S. pneumoniae strain TIGR4. DC-depleted (white symbols) and non-
depleted (black symbols) CD11c-DTR chimera mice were intranasally inoculated with 1 × 
107 CFU of S. pneumoniae TIGR4 and the bacterial loads were determined in the lungs, 
mediastinal lymph nodes, blood and spleen at 24 h post infection. Each symbol represents an 
individual animal. Solid horizontal lines indicate the mean value of non-depleted mice, 
whereas broken lines designate the mean value of DC-depleted animals. One representative 
experiment out of two is shown. *, p < 0.05. 
 
A potential effect of DT per se on the course of pneumococcal infection was examined by 
administering DT (or PBS as a control) daily into normal BALB/c mice. The application of 
DT intraperitoneally started two days before infection with S. pneumoniae D39. DT-treated 
BALB/c mice exhibited no significant differences in the bacterial loads in the organs at 24 
and 48 h of infection (Fig. 11). This result demonstrates that DT per se is not responsible for 
the enhanced resistance of DT-treated CD11c-CTR chimera mice to S. pneumoniae infection. 
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Figure 11: Bacterial burdens in the organs of BALB/c mice after intraperitoneal challenge 
with DT or PBS and subsequent intranasal infection with S. pneumoniae. DT-treated (white 
symbols) or PBS-treated (black symbols) BALB/c mice were intranasally inoculated with 1 × 
108 CFU of S. pneumoniae D39 and the bacterial loads determined in the lungs (A), 
mediastinal lymph nodes (B), blood (C) and spleen (D) at 24 and 48 h of infection. Each 
symbol represents an individual animal. Horizontal solid lines indicate the mean value of 
PBS-treated mice, whereas broken lines designate the mean value of DT-treated animals. One 
representative experiment out of two is shown. 
 
4.2. DC-depleted mice exhibit lower levels of systemic inflammation after 
intranasal inoculation with S. pneumoniae than non-depleted mice 
Among the factors important for orchestrating the inflammatory responses are cytokines as 
well as chemokines because they are responsible for the recruitment of leukocytes to the site 
of infection. Determination of the serum levels of cytokines/chemokines in DC-depleted and 
non-depleted mice at progressive time points after bacterial inoculation demonstrated that the 
systemic inflammatory response triggered by S. pneumoniae was much more tempered in the 
absence of DCs. Thus, significantly lower levels of circulating serum cytokines IL-6 (Fig. 
12A) and IFN-γ (Fig. 12B) as well as serum chemokines IP-10 (interferon gamma-induced 
protein 10) (Fig. 12C), MIG (monokine induced by gamma-interferon) (Fig. 12D) and KC 
(Fig. 12E) were detected at 72 h of infection in DC-depleted rather than non-depleted mice. 
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Figure 12: Kinetics of serum cytokines/chemokines in DC-depleted and non-depleted CD11c-
DTR chimera mice during the course of S. pneumoniae infection. DC-depleted (white 
symbols) and non-depleted (black symbols) mice were challenged intranasally with 1 × 108 
CFU of S. pneumoniae D39 and the levels of IL-6 (A), IFN-γ (B), IP-10(C), MIG (D) and KC 
(E) in serum were determined by multiplex technology at progressive times after bacterial 
inoculation. Each symbol represents the mean ± SD of the compilation of three independent 
experiments. *, p < 0.05 and **, p < 0.01. 
 
4.3. Depletion of DCs does not affect the recruitment of leukocytes into the 
S. pneumoniae-infected lungs 
Since depletion of DCs has been shown to have a beneficial effect on the host response to 
intranasal challenge with S. pneumoniae, this raises the question of whether other immune 
cells compensate for the lack of DCs, resulting in enhanced bacterial clearance. Therefore, the 
total amount as well as the subset composition of cells recruited into the lungs of CD11c-DTR 
chimera mice was determined before and during S. pneumoniae infection. The total amount of 
cells recruited into the S. pneumoniae-infected lungs was increased and in the same amount in 
DC-depleted and non-depleted mice (Fig.13A). The analysis of the different subsets of 
immune cells recruited to the lungs of infected CD11c-DTR chimera mice revealed no 
significant differences whether DCs were depleted or not. Thus, macrophages (Fig. 13B), 
CD4+ T cells (Fig. 13C) and CD8+ T cells (Fig. 13D) were recruited in comparable amounts 
into the lungs of DC-depleted and non-depleted mice. 
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Figure 13: Recruitment of different immune cell populations into the lungs of DC-depleted 
and non-depleted CD11c-DTR chimera mice during the course of S. pneumoniae infection. 
Cells were counted (A) and the infiltration of macrophages (B), CD4+ T cells (C) and CD8+ T 
cells (D) into the lungs of DC-depleted (white symbols) and non-depleted (black symbols) 
CD11c-DTR chimera mice before and at 24 and 48 h after intranasal infection with 
S. pneumoniae D39 was determined by flow cytometry. Each symbol represents the mean ± 
SD of the compilation of three independent experiments. 
 
Furthermore, monitoring the infiltration of neutrophils into the lungs of CD11c-DTR chimera 
mice revealed a significant increase in the lungs of uninfected DC-depleted mice (Fig. 14A). 
In line with this, the levels of the neutrophil-attracting chemokines KC and MIP-2 were 
significantly increased in uninfected lungs of CD11c-DTR chimera mice after DC depletion 
(Fig. 14B and 14C). No significant differences were observed in the recruitment of 
neutrophils (Fig. 14A), levels of KC (Fig. 14B) and levels of MIP-2 (Fig. 14C) in the lungs 
between S. pneumoniae-infected DC-depleted and non-depleted mice. The increase in the 
amount of neutrophils as a consequence of DC-depletion has also been previously reported 
[223]. 
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Figure 14: Neutrophil infiltration and neutrophil-attracting chemokine production in the lungs 
of CD11c-DTR chimera mice in the course of S. pneumoniae infection. (A) Infiltration of 
neutrophils into the lungs of DC-depleted (white symbols) and non-depleted (black symbols) 
CD11c-DTR chimera mice at progressive time points after intranasal infection with 
S. pneumoniae D39. Concentration of neutrophil-specific chemokines KC (B) and MIP-2 (C) 
in the lungs of DC-depleted and non-depleted CD11c-CTR chimera mice at progressive time 
points after inoculation with S. pneumoniae D39. Each symbol represents the mean ± SD of 
the compilation of three independent experiments. *, p < 0.05 and **, p < 0.01. 
 
Neutrophils play a key role in the front-line of defense against invading pathogens and have 
indeed been shown to play a major role in the host defense mechanism during bacterial 
pneumonia [224]. To determine whether the increased amount of neutrophils in the lungs of 
DC-depleted mice could be responsible for their superior resistance to S. pneumoniae, 
CD11c-DTR chimera mice were either depleted of neutrophils or of both DCs and 
neutrophils. In both groups, DC-depleted and control mice, the depletion of neutrophils 
resulted in significantly enhanced bacterial loads in the lungs (Fig. 15A), demonstrating that 
neutrophils are crucial for efficient clearance of S. pneumoniae. However, the amount of 
pneumococci in the lungs of neutrophil-depleted mice was significantly greater than in 
neutrophil/DC-depleted animals (Fig. 15A). Whereas all neutrophil-depleted mice exhibited 
higher bacterial loads in the draining mediastinal lymph nodes, just one half of the 
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neutrophil/DC-depleted mice had colonized lymph nodes as well as very low amounts of 
bacteria (Fig. 15B). Furthermore, a significant fraction (75%) of the neutrophils-depleted 
mice was bacteremic, although none of the neutrophil/DC-depleted animals exhibited 
pneumococci in the blood (Fig. 15C). The amount of bacteria in the spleen was also 
significantly higher in neutrophil-depleted than in neutrophil/DC-depleted mice (Fig. 15D). 
Taken together, these results demonstrate that the improved resistance of DC-depleted 
CD11c-DTR chimera mice to S. pneumoniae was neither depending on a more efficient 
recruitment of neutrophils nor on other immune cells. 
 
 
Figure 15: Bacterial burdens in the organs of DC-depleted and non-depleted mice after 
neutrophil depletion and challenge with S. pneumoniae. CD11c-DTR chimera mice were 
depleted of either DCs, neutrophils or both cell populations and intranasally infected with 1 × 
108 CFU of S. pneumoniae D39. Bacterial loads in the lungs (A), mediastinal lymph nodes 
(B), blood (C) and spleen (D) were determined at 48 h of infection. Each symbol represents 
an individual mouse. One representative experiment out of three is shown. *, p < 0.05; **, p < 
0.01 and ***, p < 0.001. 
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4.4. S. pneumoniae disseminates from the lungs to the mediastinal lymph nodes in 
a cell-independent manner 
The improved host resistance to S. pneumoniae in DC-depleted mice was not due to a more 
efficient recruitment and bacterial clearance by immune cells. This raises the question of how 
DCs facilitate disease progression of S. pneumoniae infection. As mentioned before, 
S. pneumoniae disseminated from the lungs to the draining lymph nodes to a higher extent 
than in DC-deficient mice (Fig. 9). Actually, it has been shown that DCs can be manipulated 
and used as a “Trojan horse” by different pathogens to promote bacterial spreading [225-227]. 
Therefore, it was investigated whether the pneumococcus uses a similar strategy for its 
extrapulmonary dissemination. Since expression of CCR7 is crucial for the migration of DCs 
to the draining lymph nodes [228, 229] the capability of DCs to up-regulate CCR7 in response 
to S. pneumoniae was determined. Flow cytometric analysis of S. pneumoniae-infected bone 
marrow-derived DCs revealed an up-regulation of CCR7 on DCs (Fig. 16A). The degree of 
CCR7 expression was dependent on the infecting dose of S. pneumoniae since increasing 
levels of CCR7 expression were observed in DCs after exposure to increasing bacterial 
inocula (Fig. 16A). Thus, in vitro infection of DCs with S. pneumoniae triggered CCR7 
expression on DCs, thereby conferring the DCs with the facility to migrate. The migration of 
DCs in response to S. pneumoniae was also demonstrated in vivo after determination of the 
amount of DCs in the mediastinal lymph nodes of S. pneumoniae-infected mice (Fig. 16B). 
After bacterial inoculation, the number of DCs increased in the lymph nodes of infected mice 
in a time-dependent manner, whereas no infiltration of DCs could be detected in DC-depleted 
mice (Fig. 16B). However, the results of the gentamicin protection assays, which allow the 
discrimination of viable intracellular and extracellular bacteria, indicated that pneumococci 
were found extracellularly rather than intracellularly within the lymph nodes (Fig. 16C). 
These results suggest that S. pneumoniae disseminated from the lungs and into the regional 
lymph nodes in a cell-independent manner and that this mode was much more efficient in the 
presence of DCs. 
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Figure 16: Expression of the chemokine receptor CCR7 on bone marrow-derived DCs and in 
vivo trafficking of DCs to the mediastinal lymph nodes after intranasal infection with 
S. pneumoniae. (A) Bone marrow-derived DCs were either left untreated (white bar) or were 
infected with different MOI (5:1, 25:1 and 50:1) of S. pneumoniae D39. The expression of 
CCR7 was analyzed by flow cytometry using anti-mouse CCR7 antibodies. (B) Total amount 
of DCs in the mediastinal lymph nodes of DC-depleted (white symbols) and non-depleted 
(black symbols) CD11c-DTR chimera mice at progressive time points after intranasal 
infection with 1 × 108 CFU of S. pneumoniae D39. Lymph node cells were counted, stained 
with anti-mouse CD11c and anti-mouse CD11b antibodies and analyzed by flow cytometry. 
Each symbol represents the mean ± SD of three independent experiments. (C) Quantification 
of viable intracellular (white bars) and extracellular (black bars) S. pneumoniae D39 in the 
mediastinal lymph nodes of infected BALB/c mice at 24 and 48 h after bacterial inoculation. 
Each bar represents the mean ± SD of triplicate samples. One representative experiment out of 
three is shown. *, p < 0.05; **, p < 0.01 and ***, p < 0.001. 
 
4.5. S. pneumoniae induces expression of MMP-9 in DCs 
When DCs migrate from the site of infection to the draining lymph nodes they have to 
overcome the barrier of ECMs and basal membranes (BMs). To this end DCs produce 
enzymes with proteolytic activity such as MMPs. MMPs, especially MMP-9, have the ability 
to degrade collagen, which is the major component responsible for the barrier function of 
RESULTS 
 
44 
 
ECM and BM. Recent publications [230-233] have reported that some pathogens are able to 
induce the production and activation of MMP-9 in various cell types to enhance vascular or 
endothelial permeability thereby promoting their own dissemination. Therefore, the capacity 
of S. pneumoniae to induce the production of MMP-9 by DCs was evaluated. Infection of in 
vitro-cultured bone marrow-derived DCs with S. pneumoniae resulted in an up-regulation of 
the mmp-9 gene (Fig. 17A). The expression of the mmp-9 gene increased more than 2-fold in 
S. pneumoniae-infected DCs over the levels observed in uninfected DCs after six hours of 
infection and up to 3.5-fold at 24 h post infection (Fig. 17A). Not only the expression of 
MMP-9 was induced in DCs after the challenge with S. pneumoniae but also the activation of 
the proteolytic activity of MMP-9 as demonstrated by the proteolytic activity of culture 
supernatants originated from S. pneumoniae-infected bone marrow-derived DCs at 24 h post 
infection by gelatin gel zymography (Fig. 17B). 
 
 
Figure 17: Expression and activation of MMP-9 in bone marrow-derived DCs after exposure 
to S. pneumoniae. (A) Bone marrow-derived DCs were infected with S. pneumoniae D39 
(MOI 20:1), RNA was extracted from DCs at 6 and 24 h post infection and subjected to real-
time RT-PCR for quantification of mmp-9 gene expression. Results are expressed as fold-
change in MMP-9 mRNA of infected DCs over the amount of MMP-9 mRNA in uninfected 
DCs. Each bar represents the mean of three independent experiments. (B) Representative 
gelatin gel zymography demonstrating the enhanced activation of MMP-9 in the culture 
supernatant of S. pneumoniae-infected DCs at 24 h post infection compared to the supernatant 
of uninfected DCs. 
 
The proteolytic activity of the S. pneumoniae-stimulated DCs was also demonstrated by the 
enhanced endothelial permeability in in vivo vascular permeability assays. In these 
experiments, culture supernatant of uninfected and S. pneumoniae-infected bone marrow-
derived DCs was injected intradermally into the dorsal skin of mice, which have been 
previously intravenously injected with Evans blue. The photograph displayed in Fig. 18A 
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shows the areas of the skin where the Evans blue was leaking into the tissue after injection of 
culture supernatant of either S. pneumoniae alone (1), untreated DCs (2) or of S. pneumoniae-
infected DCs (3). Notably, the area underneath the culture supernatant of S. pneumoniae-
infected DCs was larger than the areas beneath the supernatant from S. pneumoniae or the 
supernatant from untreated DCs (Fig. 18A). To quantify the degree of the vascular 
permeability, the areas of Evans blue extravasation were measured, dissected and the amount 
of Evans blue quantified as described in the Materials and Methods section (section 3.2.13.). 
The amount of extravasate Evans blue was significantly increased in the area injected with 
supernatant obtained from S. pneumoniae-infected DCs when compared with that of 
S. pneumoniae or supernatant from untreated DCs (Fig. 18B). 
 
 
 
Figure 18: S. pneumoniae enhances the induction of vascular permeability by DCs. (A) 
Vascular permeability induced by the culture supernatant derived from either S. pneumoniae 
D39 (1), untreated DCs (2) or S. pneumoniae-infected DCs (3). Supernatant (50 µl) was 
collected after 24 h, intradermally applied into the skin of Evans blue-treated mice and 
vascular leakage of Evans blue was visualized 1 h thereafter. A representative experiment out 
of three is shown. (B) Quantification of Evans blue leakage in the skin of mice after 
application of supernatant from S. pneumoniae D39, untreated DCs or S. pneumoniae-infected 
DCs. Each bar represents the mean ± SD of three independent experiments. **, p < 0.01. 
 
4.5. Depletion of DCs resulted in marked reduction in the expression of MMP-9 
in the lungs of S. pneumoniae-infected mice 
Although DCs have been demonstrated to produce MMP-9 during S. pneumoniae infection in 
vitro, it was still necessary to demonstrate that MMP-9 is up-regulated in the lungs during 
pneumococcal pneumonia and that DCs are involved in the production of this 
metalloproteinase during infection. Hence, the expression of the mmp-9 gene was analyzed in 
lung homogenates of S. pneumoniae-infected BALB/c mice by real-time RT-PCR. As shown 
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in Fig. 19A, mmp-9 gene expression was significantly up-regulated in the lungs of 
S. pneumoniae-infected mice with a mean fold-change increase over the uninfected lungs of 
4.36 at 24 h and 2.04 at 72 h of infection (Fig. 19A). 
To determine the impact of DC depletion on the production of MMP-9 in the lungs during 
pneumococcal pneumonia, real-time RT-PCR analysis of RNA extracted from lungs of DC-
depleted and non-depleted CD11c-DTR chimera mice at 24 h after intranasal challenge with 
S. pneumoniae was performed. Depletion of DCs resulted in significant reduction in the levels 
of mmp-9 gene expression in the infected lungs (mean fold-change of 8.23 in non-depleted 
versus 2.63 fold-change in DC-depleted mice) (Fig. 19B).  
As a wide variety of matrix proteins can be also metabolized by the gelatinase MMP-2 [181], 
the expression of the gene encoding this metalloproteinase was investigated in the lungs of 
S. pneumoniae-infected CD11c-DTR chimera mice. In contrast to MMP-9, gene expression of 
MMP-2 remained unchanged (mean fold change of 0.94) in the lungs of CD11c-DTR chimera 
mice after intranasal challenge with S. pneumoniae (Fig. 19C). Furthermore, no difference in 
the mmp-2 expression was observed between DC-depleted and non-depleted mice (mean fold-
change of 0.94 in non-depleted mice versus 0.76 in DC-depleted CD11c-DTR chimera mice) 
(Fig. 19C). These results indicate that MMP-2 plays a minor role in the lungs during 
S. pneumoniae infection. Thus, DCs are involved in the production of MMP-9 but not in the 
production of MMP-2 during pneumococcal pneumonia. 
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Figure 19: Expression of the mmp-9 and mmp-2 genes in the lungs of S. pneumoniae-infected 
mice. (A) Up-regulation of mmp-9 gene expression in the lungs of BALB/c mice at 
progressive times after intranasal infection with 1 × 108 CFU of S. pneumoniae D39. (B) Up-
regulation of mmp-9 gene expression in the lungs of DC-depleted (white bar) and non-
depleted (black bar) CD11c-DTR chimera mice at 24 h of infection with 1 × 108 CFU of 
S. pneumoniae D39. (C) Expression of the mmp-2 gene in the lungs of DC-depleted (white 
bar) and non-depleted (black bar) CD11c-DTR chimera mice at 24 h of infection with 1 × 108 
CFU of S. pneumoniae D39. Results are expressed as fold-change in MMP-9 and MMP-2 
mRNA in infected lungs over the amount of MMP-9 and MMP-2 mRNA in uninfected lungs, 
respectively. Each bar represents the mean value of three independent experiments. *, p < 
0.05. 
 
4.7. S. pneumoniae induces partial maturation of bone marrow-derived DCs 
To further investigate the response of murine DCs to S. pneumoniae, the phenotypic 
maturation of S. pneumoniae-stimulated bone marrow-derived DCs was analyzed by flow 
cytometry analysis of maturation markers and by detection of pro-inflammatory cytokines in 
the culture supernatant using ELISA. LPS was used as a positive control for the maturation of 
DCs. During the maturation process DCs up-regulate the expression of the surface molecules 
CD40, CD80, CD86 and MHC class II as well as the production of pro-inflammatory 
cytokines such as IL-6, TNF-α and in particular IL-12 [172]. These molecules are necessary 
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for efficient T cell activation and induction of adaptive immune responses [234]. 
S. pneumoniae induced a significant up-regulation of the costimulatory molecules CD80 (Fig. 
20 and 21B) and CD86 (Fig. 20 and 21C) on murine bone marrow-derived DCs compared to 
uninfected DCs. In contrast, the maturation markers CD40 (Fig. 20 and 21A) and MHC class 
II (Fig. 20 and 21D) remained unchanged. 
 
 
Figure 20: Representative single-parameter histograms showing cell surface expression of 
maturation markers on bone marrow-derived DCs after challenge with S. pneumoniae. Bone 
marrow-derived DCs were either left untreated, infected with S. pneumoniae D39 (MOI 20:1) 
or treated with 1 µg/mL of LPS. DCs were collected after 24 h and stained for the expression 
of CD11c as well as for the expression of maturation markers CD40, CD80, CD86 and MHC 
class II and analyzed by flow cytometry. Histograms depicting the fluorescence intensity of 
DCs stained with antibodies against specific markers (thick lines) are overlaid on histograms 
of cells incubated with the isotype control antibody (thin lines). The numbers in each panel 
indicate the mean fluorescence intensity (MFI) of the specific marker.  
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Figure 21: Quantification of cell surface expression of maturation markers on bone marrow-
derived DCs in response to S. pneumoniae infection. Bone marrow-derived DCs were either 
left untreated, infected with S. pneumoniae D39 (MOI 20:1) or treated with 1 µg/mL of LPS. 
DCs were collected after 24 h and stained for the expression of CD11c as well as for the 
expression of maturation markers CD40, CD80, CD86 and MHC class II and analyzed by 
flow cytometry. MFI of the surface molecules CD40 (A), CD80 (B), CD86 (C) and MHC 
class II (D) on the above-mentioned DCs are depicted in the graphs. Each bar represents the 
mean ± SD of triplicates. Data from one representative experiment out of three is shown. *, p 
< 0.05; **, p < 0.01 and ***, p < 0.001. 
 
Regarding the production of cytokines, S. pneumoniae-infected DCs produced higher levels 
of IL-6 and TNF-α than uninfected DCs. However, they did not reach the levels observed in 
the supernatant of LPS-stimulated DCs (Fig. 22A and 22B). Interestingly, the production of 
the pro-inflammatory cytokine IL-12 was strongly down-regulated in DCs after exposure to 
S. pneumoniae (Fig. 22C). As it has been previously reported that the pneumolysin of 
S. pneumoniae induces caspase-dependent apoptosis in infected DCs [210], the possibility 
that the decreased amount of cytokines observed in the supernatant of S. pneumoniae-infected 
DCs is related to the lower viability of DCs was determined. Although infection with 
S. pneumoniae affected the viability of DCs to some extent (Fig. 22E), this cannot account for 
the reduced levels of the pro-inflammatory cytokines IL-6, TNF-α and IL-12 since the 
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expression of the chemokine KC was up-regulated to a similar extent in infected DCs 
compared to LPS-stimulated DCs (Fig. 22D), albeit LPS did not affect DC viability. Taken 
together, this data indicates that S. pneumoniae impaired full maturation of DCs. Since DCs 
play an extraordinary role as central orchestrators of innate and adaptive immune responses, 
partial maturation might strongly influence the host response to S. pneumoniae.  
 
 
Figure 22: Production of pro-inflammatory cytokines/chemokines by bone marrow-derived 
DCs after challenge with S. pneumoniae. Bone marrow-derived DCs were either infected with 
S. pneumoniae D39 (MOI 20:1), treated with 1 µg/mL of LPS or left untreated. Culture 
supernatants were collected after 24 h and the levels of IL-6 (A), TNF-α (B), IL-12 (C) and 
KC (D) were determined by ELISA. (E) DC viability was determined by analyzing the 
percentage of cells negative for Annexin V and PI using flow cytometry. Each bar represents 
the mean ± SD of triplicates. Data from one representative experiment out of three is shown. 
*, p < 0.05; **, p < 0.01 and ***, p < 0.001. 
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4.8. Inhibition of DC maturation is caused by secreted molecules of 
S. pneumoniae  
Since the S. pneumoniae-infected DCs fail to fully mature, the question arises whether the 
bacterial stimulus was too weak to induce DC full maturation or whether S. pneumoniae 
actively inhibited the maturation process. The fact that IL-12, produced to a certain extent by 
immature DCs, was completely down-regulated by DCs after exposure to S. pneumoniae 
indicated an active inhibitory effect (Fig. 22C). Since pneumolysin has been reported to 
inhibit the maturation of human DCs [210], it was investigated whether the maturation of 
murine DCs was also partially inhibited by S. pneumoniae. For this purpose, LPS-stimulated 
bone marrow-derived DCs, which had high expression of CD40 (Fig. 21A and 23A) and 
produced high levels of IL-12 (Fig. 22C and 23B) were cultured in the presence of culture 
supernatant isolated from S. pneumoniae. Flow cytometry analysis of CD40 expression on 
LPS/S. pneumoniae-treated DCs revealed a significant decrease in the level of CD40 
expression when compared to LPS-stimulated DCs (Fig. 23A). Furthermore, 
LPS/S. pneumoniae-treated DCs showed a strong reduction of IL-12 production compared to 
uninfected or LPS-treated DCs (Fig. 23B). These results indicate on the one hand that 
S. pneumoniae actively inhibits certain pathways of DC maturation and, on the other hand, 
that this inhibitory effect is mediated by a released bacterial constituent rather than by direct 
cell-cell contact.  
To further investigate if pneumolysin was involved in the inhibition of DC maturation, murine 
bone marrow-derived DCs were infected with the pneumolysin-deficient mutant D39∆ply and 
the expression of CD40 (Fig. 23A) and production of IL-12 (Fig. 23B) were determined and 
compared with that of DCs infected with the wild-type strain. D39∆ply did not induce up-
regulation of CD40 in DCs (Fig. 23A), indicating that the inhibition of this maturation 
pathway was independent of the presence/absence of pneumolysin. However, D39∆ply did 
not inhibit the production of IL-12 by DCs as opposed to the strong inhibition exerted by the 
wild-type strain (Fig. 23B). This result implicates pneumolysin in the inhibition of IL-12 
production. 
Taken together, these data demonstrate that pneumococcal pneumolysin is involved in the 
inhibition of murine DC maturation. Nevertheless, it cannot be excluded that additional 
S. pneumoniae molecule(s) are involved in this process as well. Further studies are therefore 
required to identify the mechanisms of the inhibition process.  
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Figure 23: Expression of CD40 and IL-12 by DCs after exposure to LPS, S. pneumoniae D39, 
LPS and S. pneumoniae D39 or pneumolysin-deficient S. pneumoniae (D39∆ply). Bone 
marrow-derived DCs were either left untreated, infected with S. pneumoniae D39 or 
S. pneumoniae D39∆ply (MOI 20:1), treated with 1 µg/mL of LPS or incubated 
simultaneously with LPS and culture supernatant of S. pneumoniae D39. DCs and culture 
supernatants were collected after 24 h. Cells were stained for the expression of CD11c as well 
as for the expression of maturation marker CD40 and analyzed by flow cytometry. MFI of the 
surface molecule CD40 on the above-mentioned DCs is depicted (A). IL-12 was determined 
by ELISA in the culture supernatants of the differential treated DCs (B). Each bar represents 
the mean ± SD of triplicates. Data from one representative experiment out of two is shown. *, 
p < 0.05; **, p < 0.01 and ***, p < 0.001. 
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5. Discussion 
5.1. Depletion of DCs renders mice more resistant to respiratory challenge with 
S. pneumoniae 
S. pneumoniae is an important pathogen and the cause of invasive diseases such as sepsis, 
meningitis, and pneumonia [4]. The treatment of pneumococcal infections is complicated by 
the worldwide emergence of antibiotic-resistant strains with limited treatment options [98, 
99]. Although, the current available vaccine is effective at conferring protection against 
invasive disease caused by the vaccine-serotype strains, vaccine coverage is limited, and 
replacement by non-vaccine serotypes is a serious problem [12]. Consequently, 
S. pneumoniae remains still an important public health problem being responsible for more 
than 1 million deaths every year [235]. New therapeutic strategies are therefore required to 
combat this pathogen. In this regard, therapeutic strategies based on the modulation or fine-
tuning of the host immune response to kill the pathogen more efficiently may provide a new 
option in the treatment of pneumococcal infections. However, the development of such 
strategies requires a better understanding of the host immune response to S. pneumoniae. 
Because DCs are among the first immune cells which come in contact with invading 
pathogens and who are critical for inducing and shaping the pathogen-specific immune 
responses [236], the objective of this thesis was to elucidate the role played by DCs during 
S. pneumoniae infection.  
A mouse model (CD11c-DTR chimera mice) that allows the conditional and transient 
depletion of CD11c+ cells, in particular DCs, was used to define the impact of DCs in host 
defense against respiratory infection with S. pneumoniae. Remarkably, the depletion of DCs 
rendered CD11c-DTR chimera mice more resistant to pneumococcal infection, demonstrated 
by reduced bacterial loads in the organs, delayed bacterial dissemination and reduced cytokine 
and chemokine levels in the serum when compared with non-depleted mice (Fig. 9 and Fig. 
12). As not only DCs but also alveolar macrophages are depleted in the CD11c-DTR chimera 
mice [222], it was not possible to ascribe the increased resistance of mice to S. pneumoniae 
solely to the depletion of DCs. However, based on the report of Knapp et al. [145] 
demonstrating that in vivo depletion of alveolar macrophages alone by intranasal instillation 
of liposomal dichloromethylene-bisphosphonate prior to infection with S. pneumoniae 
significantly increased the mortality of infected animals [145], it was conceivable to attribute 
the enhanced resistance of mice to S. pneumoniae infection exclusively to the depletion of 
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DCs. Furthermore, the results of this work are consistent with the previous study of Winter et 
al. [237] in which increased amount of DCs in the blood and lungs of mice after 
administration of FMS-like tyrosine kinase 3 ligand (Flt3L) resulted in enhanced mortality 
and morbidity of mice after intratracheal instillation of S. pneumoniae. Together, these 
observations indicate that DCs might have an adverse rather than a beneficial effect on the 
outcome of pneumococcal pneumonia. Moreover, the improved resistance to infection with 
S. pneumoniae was neither strain specific (Fig. 10) nor dependent on a side effect of DT 
treatment per se (Fig. 11).  
The results of this thesis also demonstrated that the enhanced resistance to S. pneumoniae of 
DC-depleted mice was not mediated by an altered recruitment of inflammatory cells into the 
infected lungs. It has been previously reported that DC depletion in CD11c-DTR mice after 
treatment with DT resulted in neutrophilia and enhanced recruitment of neutrophils to the 
periphery [223]. Furthermore, in the recent study of Autenrieth et al. [238] it was shown that 
depletion of DCs improved clearance of Yersinia enterocolitica by enhancing the recruitment 
of neutrophils to the infected tissue as well as by increasing the production of reactive oxygen 
species (ROS) and thereby the bactericidal activity of these phagocytic cells. This was not the 
case for S. pneumoniae infection since although DT treatment alone resulted in increased 
neutrophil infiltration into the lungs of uninfected CD11c-DTR chimera mice (Fig. 14), DC-
depleted mice were still more resistant to S. pneumoniae than non-depleted mice in the 
absence of neutrophils (Fig. 15). This can be explained by the fact that ROS do not play a role 
in controlling pneumococcal infection neither in the lungs nor in the brain and mice deficient 
in enzymes involved in ROS production were not inferior in the clearance of S. pneumoniae 
compared to control mice [239, 240]. 
 
5.2. S. pneumoniae stimulates production and activation of MMP-9 by DCs that 
might facilitate bacterial dissemination 
After pathogen recognition, respiratory DCs generally start a maturation program that 
involves the migration from the infected lungs to the mediastinal lymph nodes. During 
infection with S. pneumoniae the amount of DCs in the mediastinal lymph nodes increased 
with the progression of infection confirming the migratory capacity of these cells (Fig. 16B). 
The observation in this study that pneumococci disseminated to the local lymph nodes to a 
greater extent in the presence of DCs (Fig. 9B) might suggest that these bacteria could take 
advantage of the migratory capacity of DCs to promote their own dissemination. In this 
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regard, several pathogens including Salmonella typhimurium, Listeria monocytogenes and 
Mycobacterium tuberculosis, have been shown to enter DCs and use them as a “Trojan horse” 
to disseminate within the host [225, 241-243]. However, the fact that a high proportion of 
pneumococci within the lymphoid tissue were extracellular (Fig. 16C) suggests that 
S. pneumoniae disseminated from the lungs to the lymph nodes in a cell-free manner and not 
within eukaryotic cells.  
To migrate into the lymph nodes, S. pneumoniae has to cross the ECM and BM. In this 
regard, a role for the plasminogen/plasmin system in facilitating the transmigration of 
pneumococci through connective tissues such as the ECM has been described [91]. This 
involves the adherence of S. pneumoniae to glycoproteins of the ECM via PfbA and PavA and 
immobilization of plasminogen on the outer surface of S. pneumoniae by the plasminogen 
receptors α-enolase, GAPDH or CBPE [93, 94, 244]. In particular, the α-enolase seems to 
play a major role in the recruitment of plasminogen since a mutant lacking the binding site for 
plasminogen was barely capable to transmigrate [91]. Plasminogen immobilized on the 
bacterial surface is subsequently converted into plasmin by host-derived activators. Plasmin 
degrades the ECM components laminin and fibronectin, but is poorly active against native 
collagens and elastin [245]. Furthermore, plasmin can specifically activate host-derived 
gelatinases such as MMP-2 and MMP-9 [246, 247]. These MMPs degrade laminin and 
fibronectin, but are also highly active against collagen [246], which is the major component 
responsible for the barrier function of the ECM [96]. Under physiological conditions, MMPs 
contribute to the controlled degradation and remodeling of the ECM [248, 249], which is a 
crucial event for the migration of DCs [250-252]. On the other hand, an increased expression 
of gelatinases has been shown to correlate with the severity of diseases such as multiple 
sclerosis [253], intracerebral hemorrhage [254], bacterial meningitis [255-257] and 
tuberculosis [258]. There is also evidence that MMP-9 contributes to the severity of 
pneumococcal pneumonia [259]. Furthermore, Yasuda et al. [260] reported improved airway 
resistance to S. pneumoniae after suppression of MMP-9. The results of this study 
demonstrated that MMP-9 activity was up-regulated in the lungs of mice during 
pneumococcal pneumonia as well as on DCs after exposure to S. pneumoniae. Furthermore, 
depletion of DCs correlated with a significant decrease in MMP-9 expression in the lungs of 
S. pneumoniae-infected mice, which supports that DCs are either a direct source of MMP-9 
during pneumococcal pneumonia or that they modulate MMP-9 production by other cell 
types. The expression of other MMPs such as MMP-2 was unchanged in the lungs of mice 
after intranasal challenge with S. pneumoniae (Fig. 19C).  
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MMPs are secreted in a latent pro-form into the extracellular space which has to be activated 
by proteolytic cleavage [261]. In addition to the expression of MMP-9, S. pneumoniae 
stimulated the activation of pro-MMP-9 produced by bone marrow-derived DCs (Fig. 17B). 
Although it has been reported that S. pneumoniae produces a zinc metalloproteinase ZmpC 
that directly activates MMP-9 in vitro, the gene encoding ZmpC is not present in the strain of 
S. pneumoniae used in this study (D39) [95]. Hence, activation of MMP-9 by S. pneumoniae 
seems to be mediated by a not yet identified bacterial virulence factor. 
Based on all these observations, it can be hypothesized that the increased production of 
MMP-9 by pulmonary DCs during pneumococcal pneumonia resulted in a more efficient 
extracellular matrix breakdown thereby facilitating S. pneumoniae to cross biological barriers 
and to disseminate. In this regard, selective blockade of MMPs might be beneficial for the 
outcome of the infection and therefore provide a novel adjunct to antibiotic-based therapeutic 
intervention in pneumococcal pneumonia. Promising studies demonstrated that MMP activity 
can be inhibited with a hydroxamic acid-based inhibitor which reduced mortality of 
pneumococcal meningitis in a rat model [262] or by chemically modified tetracyclines that 
reduced mortality of rats in a sepsis model [263]. However, since MMPs are host-derived 
enzymes, the possibility that MMP inhibitors might block normal physiological functions 
with subsequent side effects should be carefully considered. 
 
5.3. S. pneumoniae inhibits the maturation of bone marrow-derived DCs 
The maturation of DCs is crucial for the orchestration of innate immune responses and the 
initiation of adaptive immunity. S. pneumoniae induced only partial maturation of murine 
bone marrow-derived DCs in vitro characterized by high surface expression of CD80 and 
CD86, diminished expression of CD40 and MHC class II as well as a complete abrogation of 
IL-12 (Fig. 21 and Fig. 22). Since these molecules, particularly IL-12, are needed to prime 
naive T cells to become effector T cells [264], impairing DC maturation might be an 
advantageous mechanism of S. pneumoniae to escape the host immune response. Several 
bacterial pathogens have been identified which have developed mechanisms to subvert DC 
function. Mycobacterium tuberculosis interferes with TLR signaling via the C-type lectin DC-
SIGN, blocking DC maturation and IL-12 production [265]. Instead, DCs secrete IL-10, 
which directs the immune response towards immune suppression that contributes to the 
chronic carriage of this pathogen. Similarly, Bordetella pertussis-infected DCs secrete IL-10 
and activate Treg cells that suppress a protective immune response and enhance colonization 
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of the lower respiratory tract [174, 266]. In addition, several studies have shown that 
Salmonella typhimurium induces secretion of pro-inflammatory cytokines [267, 268], but it is 
able to block MHC class II antigen presentation in bone marrow-derived DCs [269, 270]. 
Another bacterial pathogen, Francisella tularensis, which induces phenotypic maturation of 
DCs, has been shown to inhibit secretion of pro-inflammatory cytokines such as TNF-α while 
eliciting production of immunosuppressive cytokines that facilitate pulmonary infection 
[271]. 
In addition, results of this study indicate that S. pneumoniae is also capable to inhibit LPS-
driven maturation of murine bone marrow-derived DCs (Fig. 23). Such inhibitory capacity 
has also been described for the human cytomegalovirus [272] and the filamentous 
hemagglutinin of Bordetella pertussis that inhibit LPS-induced IL-12 and inflammatory 
chemokine production by DCs [174].  
Regarding the S. pneumoniae factors involved in the inhibition of IL-12 production, Littmann 
et al. [210] demonstrated that the cholesterol-dependent cytotoxin pneumolysin inhibits the 
activation of human DCs. S. pneumoniae impaired the expression of co-stimulatory molecules 
CD80 and CD86 and inhibited the production of IL-12 by human DCs. Furthermore, infection 
of human DCs with a pneumolysin-deficient mutant caused significantly less severe inhibition 
of DC maturation than the wild-type strain. Similar results have been revealed in this study 
using murine DCs. The lack of CD40 up-regulation by DCs was independent of the presence 
or absence of pneumolysin. In contrast, the pneumolysin-deficient mutant D39∆ply failed to 
inhibit the IL-12 production by DCs confirming the direct involvement of this cytotoxin in the 
IL-12 inhibition. 
In summary, the current study provides direct in vivo evidence that S. pneumoniae exploits 
DCs to disseminate from the initial site of infection. Furthermore, in vitro data demonstrate 
that this pathogen modulates DC functions by interfering with the maturation process. 
Therefore, DCs might provide an interesting therapeutic target during pneumococcal 
pneumonia to prevent or delay extrapulmonary bacterial dissemination as well as to induce 
protective immune responses.  
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7. Appendix 
7.1. List of abbreviations 
Table 5: Abbreviations 
°C  degree Celsius  
3´ three prime end 
5´ five prime end 
7-AAD 7-amino-actinomycin 
Ab antibody 
ACK ammonium-chloride-potassium 
ad ad (Latin ‘up to’) 
ADP adenosindiphosphat 
AOM acute otitis media 
AP-1 activator protein 1 
APC antigen presenting cell 
Aq. dest aqua destillata (Latin ‘distilled water’) 
BM basal membrane 
C3 complement component 3 
CBP choline-binding protein 
CCL chemokine (C-C-motif) ligand 
CCR chemokine (C-C-motif) receptor 
CD  cluster of differentiation  
cDNA complementary deoxyribonucleic acid 
CFU  colony forming units  
CO2 carbon dioxide 
COPD chronic obstructive pulmonary disease 
CpG cytosine-phosphate-guanosine 
CXCL chemokine (C-X-C motif) ligand 
Cya adenylate cyclase toxin 
DC  dendritic cell  
ddH2O  autoclaved MilliQ water 
DMSO Dimethyl sulfoxide 
DNA deoxyribonucleic acid 
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DT  diphtheria toxin  
DTR diphtheria toxin receptor 
ECM extracellular matrix 
EDTA  ethylenediaminetetraacetic acid  
EF elongation factor 
ELISA Enzyme-Linked Immunosorbent Assay 
EndA endonuclease A 
et al et alii (Latin ‘and others’) 
FACS fluorescence-activated cell sorting 
Fc fragment, crystallisable 
FCS  fetal calf serum  
FHA filamentous hemagglutinin 
Fig figure 
FITC Fluorescein isothiocyanat 
Flt3L FMS-like tyrosine kinase 3 ligand 
FMS  receptor to the macrophage colony-stimulating factor 
g gram 
g g-force 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GM-CSF granulocyte-macrophage colony-stimulating factor 
h hour  
H2O water 
IFN interferon 
IL interleukin 
IP interferon gamma-induced protein 
KC keratinocyte chemoattractant 
kg kilogram 
L liter 
log logarithm 
LPS  lipopolysaccaride  
LTA lipoteichoic acid 
M molarity 
MARCO macrophage receptor with collagenous structure 
MFI mean fluorescence intensity 
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MHC  major histocompatibility complex  
MIG monokine induced by gamma-interferon 
min  minute  
MIP macrophage inflammatory protein 
mL milliliter  
mM  millimol 
MMP matrix metalloproteinase 
MOI  multiplicity of infection  
mRNA messenger ribonucleic acid 
NET neutrophil extracellular traps 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
ng nanogram 
NK natural killer 
nm  nanometer  
NOD non-obese diabetic 
ø diameter 
OD600 optical density at 600 nm 
P value probability value 
PAFR platelet-activating factor receptor 
Pav pneumococcal adherence and virulence factor 
PBS  phosphate buffered saline  
PCR polymerase chain reaction 
PE phycoerythrin 
Pfb plasmin- and fibronectin-binding protein 
pH  potentia Hydrogenii  
ply gene encoding pneumolysin 
Ppm putative proteinase maturation protein 
PPV pneumococcal polysaccharide vaccine 
PRR pattern recognition receptor 
Psa pneumococcal surface adhesin 
Psp pneumococcal surface protein 
PVC polysaccharide conjugated vaccine 
RNA ribonucleic acid 
ROS reactive oxygen species 
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rpm rotations per minute 
RPMI roswell park memorial institute medium 
RT room temperature 
RT-PCR reverse transcription polymerase chain reaction 
SD  standard deviation  
SDS sodium dodecyl sulphate 
sec second 
SIGN-R1 specific intracellular adhesion molecule-3 grabbing nonintegrin 
homolog-related 1 
Slr streptococcal lipoprotein rotamase 
TA teichonic acid 
TAE Tris-acetate-EDTA 
TCR T cell receptor 
TGF transforming growth factor 
TH T helper  
THY Todd-Hewitt Broth with yeast 
TIMP tissue inhibitors of matrix metalloproteinases 
TLR toll-like receptor 
TMB 3,3′,5,5′-tetramethylbenzidine 
TNF tumor necrosis factor 
Treg regulatory T cell 
Tween-20 Polyoxyethylene Sorbitan Monolaurate 
U units 
v/v volume/volume 
w/o without 
w/v weight/volume 
Zmp zinc metalloproteinase 
α alpha 
β beta 
γ gamma 
δ delta 
κ kappa 
µ micro 
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